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Abstract 
 
Congenital Central Hypoventilation Syndrome (CCHS, OMIM #209880) is a very rare neonatal 
neurological disorder characterized by a broad variety of symptoms of autonomic nervous 
system dysfunction including inadequate control of breathing (Weese-Mayer et al., 2017). It is 
often associated with Hirschsprung’s disease (HSCR) and neural crest-derived tumours (i.e. 
neuroblastoma). Frameshift mutations (5%) and polyalanine triplet expansions (from 4 to 13 
residues) (95%) have been detected in the coding region of PHOX2B, a transcription factor 
required for the development of neurons that regulate the cardiovascular, respiratory and 
digestive organs, forming the sensory and motor arms of the visceral reflex circuits. 
Consistent with its role as transcriptional regulator, transcriptional dysregulation might be an 
important mechanism of CCHS pathogenesis. CCHS is a life-long disorder for which the only 
treatment option is ventilatory support provided by tracheotomy, nasal mask or diaphragm 
pacing by phrenic nerve stimulation, as pharmacological respiratory stimulants have proved 
to be ineffective. A strong limitation to the comprehension of the pathogenesis of CCHS, and 
the development of new and effective treatment for this disease, is the missing knowledge of 
target genes regulated by PHOX2B, whose expression may be eventually dysregulated. Very 
little is known about the genes regulated by PHOX2B. Most of the genes identified so far are 
regulatory genes that encode for transcription factors and enzymes that control downstream 
processes involved in the survival and differentiation of specific neural structures, such as TH, 
DBH (Lo et al., 1999; Adachi et al., 2000), PHOX2A (Flora et al., 2001), TLX2 (Borghini et 
al.,2006), RET (Bachetti et al., 2005) MSX-1 (Revet et al., 2008), SOX10 (Nagashimada et al., 
2012), ALK (Bachetti et al., 2010) and PHOX2B itself (Cargin et al., 2005). 
The aim of this thesis was to identify new potential pharmacological targets for the development 
of drugs in order to improve the respiratory symptoms and the quality of life of CCHS 
patients.  
In the first part of my project we investigated the molecular mechanisms underlying the recovery 
of chemosensitivity, observed in two CCHS patients, following the administration of the 
progestinic desogestrel (Straus et al., 2010). In SK-N-BE(2)C cell clones, stably expressing 
nuclear progesterone receptor isoforms PR-B and PR-A, we demonstrated that 3-KDG 
treatment, active metabolite of the desogestrel, reduces the expression of PHOX2B, its target 
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genes as well as PHOX2B +7 alanine expanded protein, by means of a post-transcriptional 
mechanism. This finding provided the evidence of a direct molecular link between PHOX2B 
and desogestrel and suggested the possibility that reduction of PHOX2B mutant protein may 
contribute to the positive effects observed in the two CCHS patients. 
In the second part of my project we proposed to identify new PHOX2B target genes that can be 
deregulated in the pathology, in the future perspective that might be potential 
pharmacological targets, alternative to PHOX2B. In particular, we demonstrated that 
transcriptional dysregulation and dysfunctions of K+ and Na+ channels activity may contribute 
to the onset of respiratory problems associated with CCHS. Target directly the de-regulated 
PHOX2B target genes is an alternative pharmacological strategy to by-pass the effect on 
PHOX2B in the perspective of rescuing their activity. Since several drugs targeting these 
proteins are already used in clinics, the potential progress toward a therapeutic intervention 
to treat CCHS is today more than concrete. 
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List of abbreviations 
 
 
17-AAG   17-allylamino-17-demethoxygeldanamycin  
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CCHS   Congenital Central Hypoventilation Syndrome       
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ENS    Enteric Nervous System 
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NB    Neuroblastoma 
NHEJ    Non-homologous end joining  
NLS    Nuclear localization signal 
NMD   Nonsense-mediated RNA decay 
NPARMs  Non-Polyalanine repeat mutations  
NREM  Non-rapid eye movement 
NS     Nonsense 
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PARMs  Polyalanine repeat mutations 
Pg    Progesterone 
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PGRMC   Progesterone receptor Membrane Component  
PHOX2A  Paired like homeobox 2A 
PHOX2B  Paired like homeobox 2B 
PNS    Peripheral Nervous System 
pre-BötC  pre-Bötzinger complex  
RADICA  Respiratory and Autonomic Disorder of Infancy, Childhood, and Adulthood 
REM  Rapid eye movement 
ROHHAD Rapid-onset Obesity with Hypothalamic dysfunction, Hypoventilation and 
Autonomic Dysregulation 
RTN    retro-trapezoid nucleus 
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SOX10   SRY-related HMG-box 
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TLX2   T Cell Leukemia Homeobox 2 
TSS    Transcription start site 
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WT    Wild type 
 5 
 
Introduction 
 
Congenital Central Hypoventilation Syndrome  
 
In 1970 Mellins and colleagues reported the first case of Congenital Central Hypoventilation 
Syndrome (CCHS) (Mellins et al., 1970). They described about an infant affected by 
hypoventilation due to a “failure of automatic control of ventilation”.  CCHS (OMIM #209880) 
is also known as Ondine’s curse, name derived from an ancient German myth. The myth 
narrates the story of a man cursed by the Ondine nymph who is no longer able to breath 
autonomously during sleep (Suslo et al., 2015). CCHS is a rare life-long genetic respiratory 
disorder belonging to a group of other rare disorders with respiratory defects named RADICA 
(Respiratory and Autonomic Disorder of Infancy, Childhood, and Adulthood) (Patwari et al., 
2010; Weese-Mayer et al., 2009). These disorders have a varying presentation and are caused 
by dysfunction of autonomic nervous system (ANS) and defect in respiratory control. Among 
these diseases, CCHS and ROHHAD (Rapid-onset Obesity with Hypothalamic dysfunction, 
Hypoventilation, and Autonomic Dysregulation) exhibit the greatest respiratory control 
deficits.  
This syndrome is characterized by an abnormal ventilatory response to hypoxia and hypercapnia 
due to deficiency in autonomic respiratory control that normally functions during sleep. 
Subjects show adequate ventilation during wakefulness while have marked hypoventilation 
rate during sleep and, in the most severe cases also when they are awake (Weese-Mayer et 
al., 2010; Carroll et al., 2010). These respiratory symptoms are already present at birth or 
during early infancy and are more pronounced during non-rapid eye movement (NREM) sleep 
(Healy and Marcus 2011). However, some cases that present mild respiratory symptoms are 
diagnosed later in childhood or early adulthood, (late-onset cases LO-CCHS) following 
episodes such as anaesthesia, sedation or sleep apnea (Patwari et al., 2010; Weese-Mayer et 
al., 2010). CCHS occurs with an incidence of 1:200,000 born alive in France (Trang et al., 2005) 
and 1:148,000 in Japan (Shimokaze et al., 2015) but it could be underestimated due to the 
milder cases of CCHS and LO-CCHS not recognised or misdiagnosed. 
An adequate ventilation is guaranteed by the interaction between ventilatory muscle power and 
central respiratory drive that are able to overcome the respiratory load (Fig.1A) (Kasi et al., 
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2016). In CCHS, there is a decrease in central drive that leads to a displacement in favour of 
respiratory load with respiratory failure (Fig.1B). The reduction of the physiological response 
to increased CO2 seems to be due to abnormalities in the integration of chemoreceptor input 
to central ventilatory controllers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1 Diagram of respiratory balance. A: in a normal situation, ventilatory muscle power and central respiratory drive 
(blue box) overcome the respiratory load and guarantee adequate ventilation. B: in CCHS patients, central driver is 
decreased (blue box); ventilatory muscle power is not sufficient to overcome respiratory load thus leading to a 
respiratory failure. (From Kasi et al., 2016)  
 
 
 
 
Hypoventilation is the principal feature of this autonomic syndrome but CCHS may also be 
associated with a more generalised ANS dysregulation, including reduced pupillary response 
to light, abnormal oesophageal motility (gastroesophageal reflux, constipation), decreased 
control of the basal body temperature, sporadic and sudden profuse sweating, heart rhythm 
disturbances, impaired perception of anxiety and pain. CCHS can also cause respiratory arrest 
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which could not only be responsible for severe neurological damages but also it can be fatal if 
not adequately controlled (Weese-Mayer et al., 1999). 
Moreover, CCHS can occur alone or in association with other conditions including Hirschsprung’s 
disease (HSCR) (Vanderlaan et al., 2004; Trochet et al., 2005; Berry-Kravis et al., 2006) and 
tumours derived from neural crest precursors such as neuroblastoma (NB), 
ganglioneuroblastomas, ganglioneuromas (Bourdeaut et al., 2005; Van Limpt et al., 2004). 
HSCR (OMIM #142623) is an autonomic dysfunctions of the enteric nervous system (ENS) due to a 
defect in the development of ENS leading to the absence of formation of ganglia in the lower 
digestive tract. Aganglionosis results in a functional obstruction and the surgery is the only 
treatment for HSCR patients in order to remove the part of the gut that is not properly 
innervated (Heanue and Pachnis 2007). The aganglionic megacolon Hirschsprung’s disease 
can be isolated or associated with other syndromic disease such as CCHS and a variety of 
genes have been reported to be mutated in different HSCR cases (SOX10, ECE1, RET, NRTN, 
GDNF, PHOX2B, EDN3, EDNRB) (Tam and Garcia-Barceló 2009). The association with CCHS is 
known as “Haddad syndrome” (OMIM #209880) and occurs in 16% of CCHS patients.  
NB (OMIM #256700) is an embryonic neuroblastic tumours stemming from neuronal crest 
progenitors (Schleiermacher et al., 2014). In 50% of NB familial cases mutations that 
constitutively activate ALK (Anaplastic Lymphoma Kinase) (Mossé et al., 2008) have been 
reported, whereas PHOX2B (Paired Like Homeobox 2B) is found to be over-expressed in a 
small fraction of patients with sporadic or familiar NB. In addition, NB and CCHS occurs in 
approximately 20% of CCHS patients (Rohrer et al., 2002; Di Lascio et al., 2018). 
So far, there are no pharmacological ventilatory stimulants able to restore the normal ventilation, 
therefore patients need ventilatory supports to ensure adequate ventilation for life, at least 
during sleep by means of nasal mask, tracheostomy or diaphragmatic pacemaker 
implantation that stimulate phrenic nerve. Moreover, central hypoxia with risks of 
neurological damages and fatal consequence can results by inadequate treatment. 
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The PHOX2B gene and protein  
 
The PHOX2B gene codifies for a 314 amino acids long homeodomain-containing transcription 
factor and it is highly conserved in mammals; the human PHOX2B is 100% homologous with 
the chimpanzee, rat and mouse Phox2b. The human gene maps to chromosome 4p13 and 
consists of three exons (Fig.2). 
 The PHOX2B protein is member of the Q50 paired-like homeobox domain transcription factor 
family and has two core domains: a homeodomain (HD) and two polyalanine tracts.  
 
 
 
 
Fig.2 Schematic representation of PHOX2B gene and protein structure. Top: PHOX2B gene consists of three exons 
(pink); untranslated regions and introns are shown in light blue and black lines, respectively. The numbers below 
correspond to the length of PHOX2B exons. Bottom: 314 amino acids protein structure. The HD encoded by a region 
spanning exons 2 and 3 is showed in green. Blue boxes indicate the two nuclear localization signals (NLS 1 and 2); the 
two poly-alanine tracts of 9 and 20 residues within the C-terminal domain of the proteins are indicated in violet. In the 
20-alanine long stretch all the possible polyalanine repeat mutations (PARMs) are shown. 
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The HD region, spanning exons 2 and 3, is highly conserved among the members of the Q50 
paired-like homeodomain transcription factor family. It is a 60 amino acid long domain, 
forming a helix-loop-helix structure, able to recognize the DNA binding motif “ATTA” in the 
promoter region of PHOX2B target genes. The HD is flanked by two nuclear localization 
signals (NLSs) involved in nuclear translocation (Di Lascio et al. 2016). Furthermore, the HD is 
involved in homo- and hetero-dimerization and in particular, our laboratory provides 
evidence that PHOX2B protein is able to homodimerize and to strongly heterodimerize with 
its paralogue gene product PHOX2A (Di Lascio et al., 2016).   
The C-terminal portion of PHOX2B protein, encoded by exon 3, contains two short and stable 
polyalanine repeats of nine and 20 residues encoded by GC(N) triplets (Fig.2). Their functional 
role is still unknown but there is evidence that they are involved in the correct protein 
conformation, protein-protein interaction and DNA binding, as recently demonstrated (Di 
Lascio et al., 2016).  
Heterozygous mutations in the coding region of PHOX2B gene are responsible for CCHS. 
 
The genetics of CCHS 
 
CCHS is an autosomal dominant disease with variable expressivity and incomplete penetrance, and 
with no gender preference and most of the PHOX2B mutations are de novo mutations.  
The majority of CCHS patients (95%) present in-frame triplet duplications within the 20-Alanine 
stretch (PARM; polyalanine repeat mutations), ranging from +4 to +13 alanine residues (Fig.2, 
bottom) (Amiel et al., 2003; Weese-Mayer et al., 2003). However, the remaining 5% of CCHS 
patients present non-PARM mutations (NPARM) within exon 1, 2 or 3. These include rare 
missense (MS), nonsense (NS) and frameshift (FS) mutations and are frequently associated 
with the onset of NB or HSCR disease (Di Lascio et al., 2018). Between the NPARM mutations, 
FS mutations are the most frequent, in which the insertion or deletion of a single nucleotide 
induces a change in the open reading frame (ORF) that leads to an aberrant C-terminal region 
(reviewed in Weese-Mayer et al., 2017). NS mutations are very rare, and the generation of a 
premature stop codon implicates the production of an incomplete non-functional protein. 
Moreover, in a very few subjects with CCHS associated with HSCR disease it has been 
reported the presence of PHOX2B mutation that cause the loss of alanine residues (Di Zanni 
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et al., 2017) with a contraction of the 20 Alanine stretch. This mutation is also present in the 
general population with a low percentage (around 1-1.5%) and it may play a role as 
modifier/predisposing factor in the HSCR pathogenesis (Toyota et al., 2004). 
PARMs are almost exclusively identified in isolated CCHS patients that exhibit a respiratory 
phenotype with a clear correlation between the length of the alanine tract and the severity of 
the symptoms (Matera 2004; Berry-Krevis et al., 2006; Di Lascio et al., 2018). The +6 and +7 
Alanine insertion mutations are the most frequent mutations; the +4, +5 Alanine insertion 
mutations are associated with a milder phenotype, whereas patients carrying the longest 
expansion (+13 Alanine) show the most severe phenotype, often associated with other ANS 
dysregulations like cardiac abnormalities (Weese-Mayer et al., 2010). NPARM mutations are 
less frequent but, on the contrary, they are associated with more severe respiratory 
symptoms and with other autonomic disorders (e.g. NB and HSCR disease occur in 50% and in 
20% of NPARM patients, respectively) (Berry-Krevis et al., 2006; Di Lascio et al., 2018). 
PHOX2B mutations are required to diagnose CCHS disease; nevertheless, in few CCHS patients 
negative for PHOX2B mutation, it has been reported the presence of mutation in some genes 
under PHOX2B transcriptional control involved in the correct development of neuronal crest 
cells or with an important role in the neuronal respiratory network (Gallego 2012). The 
mutations described are located in genes such as: RET (Rearranged during Transfection), 
GDNF (Glial cell Derived Neurotrophic Factor, RET ligand), EDN3 (Endothelin 3), BDNF (Brain 
Derived Neurotrophic Factor), MASH1 (Mammalian Achaete-Scute complex homolog 1), 
PHOX2A (Paired-like Homeobox 2A), GFRA1 (GDNF Family Receptor Alpha 1), BMP2 (Bone 
Morphogenetic Protein 2) and ECE1 (Endothelin Converting Enzyme 1) and additionally, 
mutations in MYO1H (Myosin IH) have been recently found in children affected by a rare 
recessive form of CCHS (Spielmann et al., 2017). 
 The role of these non-PHOX2B mutations remain largely unknown but it possible to speculate that 
mutations in these genes could cause defect in the respiratory system similar to CCHS or CCHS 
itself. Jennings et al, reported very few cases with variable CCHS-like phenotypes due to 
variation in the copy numbers of PHOX2B with partial or whole gene deletion (Jennings et al., 
2012). 
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The role of PHOX2B in neurodevelopment 
 
PHOX2B protein, together with its paralogue gene product PHOX2A, are two transcription factors 
essential for the development of the ANS. The role of PHOX2B during neurodevelopment is 
well established and most of this information derives from experiments conducted in animal 
models, whereas the role of PHOX2B in adulthood is still an open question.  
Phox2b is expressed in neurons of both the central (CNS) and peripheral (PNS) nervous systems 
and it is essential for the maintenance of their differentiated stage and neuronal phenotype 
(Stanke et al., 1999). It has been demonstrated that in the CNS Phox2b is expressed in all 
noradrenergic neurons, in visceral motor neurons and in the hindbrain (Brunet and Pattyn 
2002). Moreover, it is expressed in neurons of the nucleus of the solitary tract (NTS), in the 
carotid bodies (CB) and in the retro-trapezoid nucleus (RTN), an important CO2-sensitive 
structure that fail to form properly in Phox2b knockout mice (Véronique Dubreuil et al., 2008). 
In the PNS, it is expressed by all autonomic ganglia in sympathetic, parasympathetic and 
enteric nervous system and in ganglia of the VII, IX and X cranial nerves. On the contrary, the 
expression of Phox2a is limited to parasympathetic and sensory ganglia and neurons of 
oculomotor and trochlear nuclei. Null Phox2a-/- mice die after birth with selective loss of the 
locus coeruleus (LC), the main noradrenergic centre in CNS (Morin et al., 1997).  
Study in adult rats revealed the expression of Phox2b in important structures in the hindbrain that 
control orofacial movement, auditory function and eyes. Moreover, it seems to be absent in 
structures involved in respiratory rhythm and pattern generator, but it is highly expressed by 
neurons that mediate chemoreflex (Kang et al., 2007). In particular Phox2b was detected in 
the dorsal vagal complex and in RTN. In neurons of the NTS it is confined to cholinergic 
efferent neurons (salivary, vestibulocochlear) and, at the level of pons it is present only in the 
oculomotor complex. The persistence of the expression of Phox2b in the brain of the adult rat 
may also have an important role in maintaining the function of the noradrenergic neurons as 
suggested by data by Fan and colleagues; they demonstrated that both Phox2a and Phox2b 
are able to upregulate the expression of two important protein (DBH and NET) in 
noradrenergic neurons of rat brain (Fan et al., 2011).  
PHOX2B plays a crucial role in determining neuronal identity during neurodevelopment. The 
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correct development of the autonomic ganglia (enteric and sympathetic) is a crucial step that 
occurs at the level of neuronal crest cell precursors and that requires mutual negative 
regulation between Phox2b and Sox10 (SRY-related HMG-box). During normal 
neurodevelopment, crest-derived precursors of sympathetic and enteric neurons initially 
express only Sox10. When they migrate to the periaortic or enteric mesenchyme, they start to 
express Phox2b becoming double positive Phox2b+/Sox10+ cells (Fig.3). At this stage the 
destiny of bipotent progenitors is still undetermined; they can form either neuron or glia. 
Sox10 is inactivated in cells that are destined to form neurons, while Phox2b is inactivated in 
cells that give rise to glia. The balance between Phox2b and Sox10 is the result of their mutual 
and reciprocal suppression and it is required for the correct maintenance and differentiation 
of progenitors in enteric and sympathetic ganglia (Nagashimada et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3 Schematic representation of the balance between Phox2b and Sox10 in glial and neuronal differentiation. 
During normal development, initially crest-derived precursors are only Sox10+. After the migration to the site of 
ganglion formation they become bipotent progenitors Phox2b+/Sox10+. The balance between Phox2b and Sox10 is the 
result of their mutual and reciprocal suppression; glial cells are Phox2b-/Sox10+, while neuron cells are Phox2b+/Sox10- 
(From Gershon 2012). 
 
 
 
 
In addition to playing a major role in the correct formation of the entire autonomic nervous 
system, PHOX2B and PHOX2A are essential for the lineage specification toward a 
noradrenergic phenotype (Tiveron, Hirsch, and Brunet 1996) and maintains neuronal 
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differentiation by regulating neuronal cell cycle exit (Dubreuil et al., 2000; Paris et al., 2006). 
Noradrenergic neurons are generally defined as neurons expressing tyrosine hydroxylase (TH) and 
DBH (Dopamine-β-hydroxylase), the rate-limiting enzymes required for the biosynthesis of 
noradrenaline. The specification of neuronal identity results from the interaction between 
intrinsic (cascades of transcription factors) and extrinsic factors (secreted or membrane 
associated signals).  At embryonic day 10, neuroblast progenitors migrate to the dorsal aorta 
region, where the secreted bone morphogenetic proteins (BMPs) induce the expression of 
other factors necessary for the acquisition of a catecholaminergic phenotype. These 
transcription factors are expressed in a specific temporal order and form a complex 
regulatory network. Briefly BMPs stimulate the expression of MASH1 and PHOX2B. MASH1 
regulates PHOX2A and the bHLH transcription factor dHand, while PHOX2B regulates 
PHOX2A, dHand and GATA3. In turns, PHOX2B, dHand and GATA3 regulate the expression of 
TH and DBH (Fig.4) (Howard 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4 Schematic representation of transcriptional cascade for the noradrenergic differentiation. The migration of 
progenitor cells to dorsal aorta region activate extrinsic factors (BMP) that activate a complex network of intrinsic 
factor that lead to the specification of noradrenergic neuronal identity (From: Howard 2005). 
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PHOX2B target genes  
 
So far, only few PHOX2B target genes have been identified. Some target genes encode proteins 
that enable neurons to perform their automatic function such as TH and DBH encoding for 
enzymes involved in the catecholamine biosynthesis, as mentioned before (Adachi et al., 
2000; Lo et al., 1999). Others are regulatory genes that encode transcription factors that 
control downstream processes involved in the survival and differentiation of specific neuronal 
structure. For example, PHOX2A and TLX2 (T Cell Leukemia Homeobox 2) are two gene 
positively regulated by PHOX2B. TLX2 is mainly expressed in tissues derived from neural crest 
cells at the end of their migration at the level of vesical and enteric nerve ganglia where it 
plays a crucial role in the development of the ENS (Borghini et al., 2006). Another 
transcriptional target of PHOX2B that play a crucial role in the correct intestinal innervation is 
the rearranged during transfection (RET) gene; a mutation in its regulatory regions is 
associated with HSCR disease (Bachetti et al., 2005). Moreover, it has been demonstrated that 
PHOX2B directly regulates the expression of the gene encoding for the receptor tyrosine 
kinase ALK; mutations in this gene are associated with NB (Bachetti et al., 2010). Furthermore, 
PHOX2B negatively regulates two important genes essential for the embryonic neuronal crest 
development: MSH homeobox 1 (MSX-1) (Revet et al., 2008) and SOX10 (Nagashimada et al., 
2012). 
From a molecular point of view, PHOX2B regulates the expression of these genes by binding to 
specific "ATTA" sequences present within the promoters of its target genes. The "ATTA" sites 
are also present within the promoter of PHOX2B itself therefore, the same PHOX2B has to be 
considered a target gene because it modulates its own expression through an auto-regulatory 
mechanism (Cargnin et al., 2005). 
This nucleotide sequence is present in the promoter region of PHOX2A and it has been 
demonstrated that PHOX2B positively regulates the expression of its paralogue gene, PHOX2A 
(Flora et al., 2001). As described in the previous chapter, PHOX2B and PHOX2A are co-
expressed in several noradrenergic neurons but their expression is temporally and spatially 
regulated. In vitro experiments demonstrated that the PHOX genes are not functionally 
equivalent. In particular, in the sympathetic and parasympathetic ganglia of the brain stem, in 
the branchiomotor and visceral motor neurons and in the enteric system the expression of 
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Phox2b is essential for the correct development and precedes the expression of Phox2a. On 
the contrary, the LC is absent in null Phox2a-/- mice suggesting that Phox2a precedes the 
expression of Phox2b in this structure. However, the LC is also partially affected by the lack of 
phox2b demonstrating that both factors are required for its proper development (Pattyn et 
al., 1999) 
PHOX2A and PHOX2B together regulate the expression of DBH, TH, ALK and TLX2; furthermore, 
PHOX2A regulate the expression of the α3 subunit of the human nicotinic acetylcholine 
receptor (α3 nAChR) in the post-ganglionic cells of the sympathetic nervous system (Benfante 
et al., 2007). 
 
The role of Phox2b in respiratory circuit and animal model of CCHS 
 
Breathing is an innate response essential for mammalian survival that ensures constant regulation 
of oxygen, carbon dioxide and hydrogen levels in the body.  A physiological ventilation is 
guaranteed by the right integration of chemoreceptor input to central ventilatory control. 
This integration appears to be altered in CCHS patients. Much of our knowledge of the basic 
mechanisms that lead to a stable respiratory model derives from animal studies, both adults 
and new-borns. Breathing cycle can be divided into three main phases: inspiration (I); post-
inspiration (Post-I or first stage of expiration) and late expiration (E2 or second stage of 
expiration) and is the result of the phasic contraction of respiratory muscles (thoracic 
muscles, muscles of the upper airway, diaphragm and expiratory muscles) that are activated 
by the spinal respiratory motor neurons. The timing of the respiratory cycle is controlled by 
excitatory and inhibitory interneurons that discharge during specific phases of the respiratory 
cycle. This complex network of neurons is called the Central Pattern Generator (CPGs) and 
represents also the centre for the integration of both motor and sensory signals (Smith et al., 
2013; Tremoureux et al., 2014). Autonomic control of breathing is anatomically positioned in 
the brainstem, on the contrary voluntary control is located in the promoter areas, cerebellum 
and primary motor cortex (Zaidi et al., 2018). 
The respiratory rhythm generator in the medulla can be separated in two groups containing 
respiratory neurons from either the dorsal or ventral respiratory group: the pre-Bötzinger 
complex (pre-BötC) (Smith et al., 1991) and the retro-trapezoid/parafacial respiratory group 
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(RTN/pFRG) (Onimaru et al., 2003). The dorsal respiratory group (DRG) is formed by 
inspiratory neurons that send signal to the motor neurons in the diaphragm, while ventral 
respiratory group (VRG) consists of both inspiratory and expiratory neurons.  
Typically, respiration is initiated by respiratory neurons activated by peripheral chemoreceptor. 
Chemoreceptors providing information about pO2, pCO2/pH influence the respiratory cycle 
and are present in the aortic arch, in the CB (peripheral chemoreceptors) and in the ventral 
part of the bulb, near the VRG (central chemoreceptors). Central chemoreceptors are widely 
distributed in the nervous system, but the two main players are: RTN (Guyenet et al., 2008; 
Guyenet et al., 2009) and bulbar serotonergic neurons of the raphe nuclei (Corcoran et al., 
2009; Hodges and Richerson 2010). 
RTN is another vital source of respiratory drive, located in the ventral medullary surface and it is a 
collection of glutamatergic neurons that express Phox2b and the vesicular glutamate 
transporter VGltu2. These neurons receive signals from CB, hypothalamus and neurons 
located in the NTS which are stimulated by afferent axon in the fasciculus solitarius tract that 
innervates the phrenic nerve nucleus and the muscles of inspiration as well as afferent 
chemoreceptor in the CB. RTN is more important during NREM than during REM sleep (Zaidi 
et al., 2018).  
CO2-sensitive structures such as the LC, area postrema, RTN and the afferent pathways from the 
CB depend on Phox2b for their development (Dubreuil et al. 2009); moreover, in adult rats, it 
has been demonstrated that inhibition or injury of RTN neurons widely attenuate the 
chemoreceptor reflex of breathing. 
Today, genetically engineered animals are still an important model to study and understanding 
better the pathophysiological mechanisms of CCHS. Studies on animal model that try to 
recapitulate CCHS disease, helped to understand the direct assessment of the role of PHOX2B 
in the neuronal control of breathing as well as its role in neuronal development and cellular 
function. 
Phox2b knockout mice (Phox2b-/-) are not vital and die in utero at E14 stage for complete agenesis 
of the ANS underlying the essential role of Phox2b in ANS development (Pattyn et al., 2000; 
Pattyn et al., 1999).  Mice bearing only one invalidated allele (Phox2b+/-), survive, are fertile 
but do not recapitulate the CCHS phenotype (Dauger 2003). In 2-day-old mice it was reported 
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an impaired ventilatory response to hypercapnia however resolved 10-days post birth. In 
comparison to adults, neonatal respiratory control is immature and the ventilatory response 
to CO2 is influenced by environment and body temperature as well as age. Ramanantosoa and 
colleagues demonstrate that Phox2b mutation affects the interaction of breathing with 
thermoregulation control (Ramanantsoa et al., 2007). The neuroanatomical bases of this 
dysfunction are not clear because thermoregulation is mediated by the hypothalamus that 
does not express Phox2b. Serotonergic neurons that are involved in both thermoregulation 
and in respiration could be involved. 
More information concerning the link between Phox2b expression and brainstem respiratory 
circuits derived from study of the first mouse model of CCHS in 2008. This model was 
obtained using a knock-in approach to insert the most frequent polyalanine expansion (+7) 
into the 20-alanine tract (Phox2b27Ala/+) (Dubreuil et al., 2008). The heterozygous mice die 
within a few hours after birth because of central apnea, blunted response to hypercapnia and 
abnormal breathing patterns in normal air; symptoms that recapitulate symptoms of human 
neonates with CCHS. Neuroanatomical studies showed loss of RTN/pFRG neurons and 
precursors population at embryonic day 12.5, whereas no abnormalities in other structures 
involved in controlling breathing were revealed.  Conditional mice (Egr2cre; Phox2blox/lox and 
Lbx1cre; Phox2blox/lox) were generated to further investigate the link between RTN and 
chemosensitivity; both mutant mice showed massive and selective depletion of RTN neurons, 
no response to hypercapnia, and died at birth due to respiratory failure (Dubreuil et al., 
2009), thus suggesting that loss of RTN/pFRG disrupts respiratory rhythmogenesis and 
chemosensitivity during early development. 
However, mice in which the selective ablation of the RTN was caused by the expression of the 
Phox2b +7 Alanine mutant only in neurons descending from the Egr2 lineage (Egr2cre; 
P2b27Alacki) survived to adulthood (Ramanantsoa et al., 2011), although they still showed 
blunted response to hypercapnia up to 4 months, that recovered in the adult stage. Taken 
together, these results support the pivotal role of RTN in CO2 sensitivity, especially during 
NREM sleep but this is not explaining the respiratory defects that these same patients have 
also during wakefulness. Moreover, since conditional mice survived despite the deletion of 
RTN, this suggests that the neurological bases of CCHS are not confined to RTN, and other 
structures can be involved. Furthermore, compensatory mechanisms could have an important 
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role in partially restoring CO2 sensitivity. 
Studies to identify the presence of RTN-like structure in humans are very difficult and are based on 
the identification of PHOX2B positive regions by immunohistochemistry analysis.  
 Analyses of post-mortem brain of two CCHS patients with confirmed PARM and NPARM 
(PHOX2BΔ8) mutation revealed important defects of the LC. In particular, patients presented 
abnormalities in dorsal motor neurons of the vagus nerve, decrease serotoninergic median 
raphe and absence of mesencephalic trigeminal nucleus (Nobuta et al., 2015). These findings 
were confirmed in a mouse model (Hprt-cre /PHOX2B20/E3-cKi-Δ8-ires-GFP) carrying the same 
NPARM mutation detected in patients, expressed at early embryonic stages (<E10.5). These 
mice died at delivery and showed intestinal aganglionosis and loss of RTN and facial nerve 
nucleus due to the failure of precursors migration. Mice also showed abnormal LC due to a 
wrong precursor differentiation with altered expression of catecholamine synthetizing 
enzymes (DBH and TH), indicating noradrenergic and LC dysfunction. In contrast, the 
expression of this NPARM mutation after neurogenesis, at E11.05 (Blbp-cre/ PHOX2B20/E3-cKi-Δ8-
ires-GFP), and limited to Phox2b+ neurons, did not affect LC development. Despite the failure of 
RTN development, the perinatal respiratory lethality was rescued (Nobuta et al., 2015). 
This data suggests that LC and RTN neurons can both contribute to the respiratory abnormalities 
of CCHS patients. 
 
Molecular pathogenetic mechanisms  
 
It is well known that CCHS is due to mutations in PHOX2B gene resulting in aberrant proteins but 
what is the exact pathogenetic role of the PHOX2B mutant protein at the molecular level is 
still unclear. Data derived from in vivo and in vitro studies suggest that the combination of at 
least three different mechanisms is responsible for the different manifestation of the clinical 
phenotypes in CCHS patients; loss-of-function mechanism, dominant-negative effect and toxic 
gain of function (Di Lascio et al., 2013; Trochet, Hong, et al., 2005; Bachetti et al., 2005; 
Durand et al., 2005; Goridis et al., 2010; Dubreuil et al., 2008) (Fig.5). The respiratory 
problems observed in the first post-natal period, in engineered mice expressing only one copy 
of Phox2b gene (Phox2b+/-) is suggestive of a haploinsufficiency mechanism in CCHS. The 
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presence of only one functional Phox2b allele although it is sufficient to prevent CCHS 
manifestation, on the other hand it contributes to the mild autonomic dysfunction of the 
post-natal period.  Haploinsufficiency is often caused by a loss-of-function mutation indeed 
mice bearing only the mutant allele +7 Ala (Phox2b -/+27 Ala) die in utero providing the evidence 
that mutation in Phox2b lead to loss-of-function. Finally, the presence of a toxic-gain of 
function mechanism in CCHS due to mutation in Phox2b gene is suggested by the lack of 
development of Phox2b positive neurons (RTN neurons) in heterozygous mice (Phox2b+27Ala/+). 
In order to better understand the role of the mutant protein in the onset of CCHS symptoms, 
experiments with PHOX2B mutant proteins bearing different polyalanine expansion and/or 
with frameshift mutations have been carried out in cellular models. Alterations in the cellular 
localisation and transcriptional activity were reported with both mutant proteins (PARM and 
NPARM) in contrast to wild type (WT) protein (Bachetti et al., 2005; Trochet et al., 2005; 
Trochet, de Pontual, et al., 2008; Di Lascio et al., 2018; Bachetti et al., 2007).  
More precisely, in vitro, all the mutant proteins show a tendency to oligomerize probably due to 
protein misfolding, however the loss of nuclear localization and the formation of cytoplasmic 
aggregation is especially evident in the mutant protein with the longest polyalanine stretch 
expansion (loss-of-function mechanism) (Bachetti et al., 2005; Trochet et al., 2005; Trochet, 
de Pontual, et al., 2008), whereas FS mutations preserve the nuclear localization with 
formation of nuclear inclusion (Di Lascio et al., 2018; Bachetti et al., 2005). The 
overexpression of PHOX2B +13 Ala in cellular model induces not only cytoplasmic aggregation 
but also cellular death by apoptotic mechanism (toxic gain of function) (Bachetti et al., 2007). 
It is important to underline that, until now, there is no evidence concerning aggregation of 
PHOX2B in vivo, so further investigations are necessary to understand the role of this 
mechanisms in CCHS.  
Moreover, studies on the transcriptional activity of PHOX2B mutant proteins reported a dominant-
negative mechanism in combination with a loss-of-function mechanism (Di Lascio et al., 
2013). In particular, mutant proteins with longer expansion retain PHOX2B WT proteins in the 
cytoplasm and interfere with the PHOX2B WT autoregulatory loop, thus leading to the 
reduction of the expression of the normal protein (Di Lascio et al., 2013; Parodi et al., 2012). 
In addition, the presence of the alanine expansion in the C-terminal portion of the protein 
decreases PHOX2B capacity to regulate the expression of important target genes such as DBH, 
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PHOX2A and TLX2 (Di Lascio et al., 2013; Bachetti et al., 2005; Trochet et al., 2005). Elongation 
of the alanine stretch in PHOX2B alters also the ability to form homo-dimers important for the 
transcriptional activity. PHOX2B proteins with long expansions and with NPARM mutation 
show a reduction in protein affinity to DNA and weakly interact with the WT protein, while 
mutant proteins with short expansions maintain this ability (Di Lascio et al., 2016; Trochet et 
al., 2005; Trochet et al., 2008).  
Moreover, PHOX2B WT protein forms hetero-dimers with PHOX2A. Data from our laboratory 
demonstrated that the mutant protein retains the ability to interact with PHOX2A without 
interfering with its nuclear localisation and above all, with its transcriptional activity (Di Lascio 
et al., 2016).  
In this perspective, the dominant-negative effect observed in the presence of the mutant protein 
is not probably due to an aberrant interaction with the WT protein but conversely to a 
mechanism of squelching of co-activators or co-repressors that are usually recruited by WT 
homo-dimer in a physiological situation. In line with this idea, it has been demonstrated that 
CREB-binding protein is a PHOX2B co-activator that mediate synergistic activation (Wu et al., 
2009). The two proteins interact by means of specific domains. In the presence of the mutant 
protein, the interaction domains are different than those used with the normal protein thus 
leading to an impaired synergistic activation, a mechanism that can contribute to the 
pathogenesis of CCHS (Wu et al., 2009). Moreover, PHOX2B protein bearing FS mutations can 
regulate PHOX2B target genes in a different way. For instance, SOX10 that is negatively 
regulated by PHOX2B during neuronal differentiation is transactivated by PHOX2B mutant 
protein (Nagashimada et al., 2012). 
CCHS occurs with a wide variety of symptoms and patients with the same mutation show different 
severity of respiratory phenotype. As in vitro studies have shown that PARM and NPARM 
mutant proteins share some of the molecular mechanism leading to impaired transcription of 
PHOX2B and its target genes, it is reasonable to suggest that different mutation may induce 
different defects by means of a combination of the three molecular mechanisms described, 
depending on the genetic background of the patient (Trochet at al., 2005). 
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Fig.5 Schematic representation of molecular pathogenesis of CCHS. Left: wild-type condition. PHOX2B (blue) and 
PHOX2A (red) proteins are translated into the cytoplasm and then migrate to the cell nucleus where they form homo- 
and hetero-dimers, bind specific DNA sequences, recruit co-activators (green), and induce the transcription of target 
genes. Right: In CCHS, one of the two PHOX2B alleles is mutated (red dot). As in the case of the WT, both copies of the 
gene are transcribed into mRNA molecules and then translated into proteins; half normal (blue circle) and half 
mutated (blue triangle). Mutated proteins are misfolded, aggregate in the cytoplasm and fail to enter into the nucleus. 
Aggregates activate heat shock proteins (HSPs) that try to refold mutant proteins or ubiquitin ligase enzymes (Ub) for 
the proteolytic degradation by the proteasome. In cell models of CCHS, the WT protein can be recruited into protein 
aggregates, which may lead to a dominant negative effect. A fraction of the mutated proteins can enter to the nucleus 
and induce transcriptional dysregulation by means of various molecular mechanisms:1) aberrant interactions with the 
cofactors important for transcriptional activity; 2) decreased transcriptional activity due to a decreased DNA binding; 
3) induction of the expression of aberrant target genes; and 4) a decreased ability to interact with PHOX2A. (From Di 
Lascio et al., 2018) 
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Therapeutic approaches in CCHS  
 
The limited knowledge regarding the genes regulated by PHOX2B and their involvement in the 
different clinical manifestations of the disease prevent the development of pharmacological 
treatments able to improve the disease-related respiratory defects and the quality of life of 
patients. So far, no pharmacological treatment has been developed and the ventilatory 
support is the only option available. 
In vivo experiments show the tendency of mutant PHOX2B protein to form aggregates. Therefore, 
a current pharmacological strategy consists in counteracting the toxic effect of aggregation 
activating the heat shock protein (HSP) response pathway (Bachetti et al., 2007; Parodi et al., 
2012). Physiologically, the presence of misfolded protein in the cytoplasm or in the nucleus is 
recognised by the cell quality control mechanisms that activate chaperon proteins in order to 
refold the protein or facilitate the activation of the ubiquitin/proteasome pathway, which 
degrades misfolded proteins. The formation of aggregates is a pathological mechanism that 
usually occurs when the production of misfolded proteins exceeds the proteolytic capacity of 
the proteasome or the activity of chaperones proteins. In line with this idea, Bachetti and 
colleagues demonstrated that geldanamycin (GA), a benzoquinone ansamycin antibiotic that 
activates the heat shock response, is able to induce cytoplasmic disaggregation. In particular, 
GA rescues the nuclear localisation and transcriptional activity of PHOX2B mutant protein 
bearing the +13 Alanine expansion (Bachetti et al., 2007). 
This strategy was then expanded to curcumin (diferuloylmethane) and to 17-allylamino-17-
demethoxygeldanamycin (17-AAG), an anticancer drug. Both compounds resulted to be 
effective in refolding and rescuing PHOX2B nuclear localization and transactivation activity 
and promoting the clearance of mutant PHOX2B protein aggregates. While GA and 17-AAG 
induce the expression of molecular chaperones HSP70, curcumin does not induce activation 
of HSP, thus suggesting the presence of an alternative pathway (Di Zanni et al., 2012). 
Other possible pharmacological targets are ubiquitin ligase enzymes (E1, E2 and E3) that are 
necessary to target misfolded protein to the degradation by proteasome proteolytic activity. 
In particular, TRIM11, an E3 ubiquitin ligase, has been found to induce DBH expression by 
directly interacting with PHOX2B. The overexpression of TRIM11 induces both mutant and WT 
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protein degradation and counteracts the dominant-negative effect of mutant protein on the 
transcription activity of DBH promoter. Mechanisms, which upregulate the expression of 
TRIM11, could be an alternative target for treatment of CCHS patients (Parodi et al., 2012).  
All systems involved in protein quality control are possible pharmacological targets, but it is 
important to underline that the presence of aggregates was demonstrated only by in vitro 
experiments with the overexpression of mutant protein. In addition, these drugs affect also 
WT PHOX2B protein, although it has been demonstrated that the presence of WT protein has 
a protective role in preventing the formation of aggregates in cell models (Di Lascio et al., 
2013). However, PHOX2B mutant proteins mislocalization is not the only mechanism 
suggested in the pathogenesis of CCHS; as already described, the mutant protein exerts a 
dominant-negative effect on WT protein activity and the refolding of aggregates may improve 
the normal protein function.  
Indeed, a PHOX2B mutant protein is not only a misfolded protein as it maintains the ability to 
interact with co-activators (Wu et al., 2009) and with PHOX2A (Di Lascio et al., 2016), 
although with different results; the binding with the co-activator CBP interferes with the 
activation mediated by the PHOX2B WT/CBP complex, whereas the heterodimerization with 
PHOX2A partially prevents transcription defect of PHOX2B mutant protein. These data 
suggest that the functional effect of the mutant protein depends on the interactor proteins 
and they could represent an important pharmacological target, alternative to PHOX2B. 
Recently, the use of progesterone has been investigated as strategy to improve respiratory 
symptoms. The idea that progesterone therapy could be useful arise from the fortuitous 
observation that two female patients, with +5 and +6 Alanine expansions, experienced a 
partial CO2-chemosensory recovery and increased ventilation under treatment with 
desogestrel for contraceptive purposes (Straus et al., 2010). It is well known that 
progesterone (Pg) and synthetic progesterone derivatives are respiratory stimulant in adult 
humans and have been used to treat adults with obesity hypoventilation disorders and are 
potential candidate for the treatment of adult apnoea (Boukari et al., 2017; Shahar et al., 
2003). Pg is a steroid mainly synthesized in the gonads and in the placenta and as a 
neurosteroid, in the peripheral and central nervous system (Nelson and Bulun 2001). Sex 
hormones can modulate breathing through a direct effect on gene expression in respiratory 
neurons (by steroid hormones receptors activation) or indirectly (Behan and Wenninger 
 24 
 
2008). Pg can bind membrane receptor or nuclear receptor expressed in several brain regions 
and activates different response: a rapid non-genomic mechanism and a slower genomic 
mechanism, respectively (Contrò et al.,2015).  
The classical nuclear progesterone receptor (PGR) is present in two isoforms, resulting from an 
alternative transcription driven by independent promoter of the same gene: the full-length B 
isoform (progesterone receptor B, PGR-B) and the N-terminal truncated isoform A 
(progesterone receptor A, PGR-A) (Conneely et al., 1987). The two isoforms have distinct role: 
PGR-B is essential for normal mammary gland development, while PGR-A is required for 
uterine development and reproductive function (Mulac-Jericevic et al., 2000; Mulac-Jericevic 
et al., 2003). However, in gene expression regulation they can also have a synergic role (Hopp 
et al., 2004). From a transcriptional point of view, PGR-A and PGR-B display different 
transcriptional regulatory activities: PGR-B is a strong activator of transcription of several 
PGR-dependent promoters whereas PGR-A is associated to a repressor activity (Mulac-
Jericevic et al., 2000).   
PGR has been localized in different region of CNS including cortex, hypothalamus, hippocampus, 
cerebellum and NTS (Bayliss and Millhorn 1992) where it plays an important role as 
modulator of chemoreflex sensitivity and respiratory control, especially during sleep (Bayliss 
et al., 1987). In addition, experiments conducted on nuclear progesterone receptor knockout 
mice (PRKO mice) demonstrated that the absence of PGR increases apnea frequency during 
NREM sleep and reduces chemoreflex responses to hypercapnia after Pg treatment 
(Marcouiller et al., 2014). 
Pg binds also to membrane receptors such as the seven Trans-Membrane Progesterone receptor 
(7TMPR) and the single transmembrane receptors Progesterone receptor Membrane 
Component 1 and 2 (PGRMC1 and PGRMC2). The 7TMPR isoform α is expressed in 
reproductive tissues and kidney, the 7TMPR isoform β is localized in neuronal tissues 
(cerebral cortex, cerebellum, thalamus, caudate nucleus, spinal cord and pituitary gland), 
whereas the 7TMPR isoform γ is present in colon and kidney (Zhu et al., 2003). PGRMC1 and 
PGRMC2 are expressed in liver, kidney and placenta, moreover they are found in 
hypothalamic nuclei of rat brain (Gerdes et al., 1998).  
Women affected by CCHS do not recovery CO2 sensitivity during gestation, thus suggesting that 
physiological progesterone is not able to improve hypercapnia response per sé (Sritippayawan 
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et al., 2002). Consequently, the effect of desogestrel is exclusively mediated by this progestin. 
The fact that desogestrel has a stronger affinity for progesterone receptor than progesterone 
itself (three times greater) could justify this effect (Grandi et al., 2014). However, the exact 
mechanism through which desogestrel could ameliorate respiratory symptoms in CCHS 
patients remains still unknown.  
Very recent findings indicate that multiple neuronal circuits, such as those involving medullary and 
supramedullary neurons, are involved in the effect mediated by desogestrel (Joubert et al. 
2016; Loiseau et al., 2014). In particular, experiments conducted in mice or in ex vivo murine 
medullary-spinal cord preparations, demonstrated an increase in respiratory frequency after 
exposition to etonogestrel (active metabolite of desogestrel), mediated by the activation of 
the medullary respiratory neurons, in particular serotoninergic neurons of the raphe pallidus 
and nucleus raphe obscurus (Joubert et al., 2016). In addition, other experiments on ex vivo 
preparations of CNS (medullary–spinal cord and diencephalon–brainstem–spinal cord 
preparation) of new-born rats, demonstrated that acute exposure to etonogestrel involves 
supramedullary structures located in pontine, mesencephalic or diencephalic regions (Loiseau 
et al., 2014). It is worth noting that the same regions activated by desogestrel express Phox2b 
in adulthood rodent brain (Kang et al., 2007). All together these data indicate that more than 
one neuronal circuit should be considered in the chemosensitivity recovery observed in the 
two CCHS patients after desogestrel treatment. 
So far CCHS has been considered a neurodevelopmental disorder resulting from total disruption of 
central chemosensory integration. However, data from heterozygous animal models carrying 
the Phox2b +7 Alanine mutation (Trochet et al., 2008) suggest the possibility of residual 
chemosensory function in the human disease. In fact, these animals showed a reduction by 
70% of the crucial RTN chemoreceptor function. The hypothesis of a residual chemosensitivity 
response was confirmed recently in CCHS patients by Carroll and colleagues (Carroll et al., 
2014). In a large cohort of CCHS patients and in particular in young patients, they reported a 
detectable, although still physiologically inadequate, ventilatory response to chemosensory 
challenges. This residual cardiorespiratory response suggests a partial preservation of CNS 
networks; this could provide a pivot for potential pharmacological interventions capable to 
take advantage of this function to reduce mortality and morbidity while enhancing the overall 
quality of life in patients with CCHS. 
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Aim of the thesis  
 
For many years, it was thought that CCHS was an irreversible disease for two main reasons: first of 
all, it is a neurodevelopmental disorder and second because CCHS mice model show missing 
formation of RTN, a crucial structure responsible for hypoxia and hypercapnia sensitivity, thus 
frustrating any effort to restore CO2 chemosensitivity in CCHS patients (Carroll et al., 2014). 
However, recent studies reported the presence of a residual cardiorespiratory response in 
CCHS patients (Trochet et al., 2008). This finding opens up the possibility to search for 
potential pharmacological interventions capable to take advantage of this residual function to 
reduce mortality and morbidity while enhancing the overall quality of life in patients with 
CCHS.  
In 2010 a hopeful indication for the treatment of CCHS patients derived from a direct clinic 
observation (Straus et al., 2010). It has been observed that two female patients (20/25 and 
20/26 genotype), using a progestin drug, desogestrel, for contraceptive purposes, dramatically 
ameliorated the clinical symptoms of CCHS, showing chemosensitivity recovery. This 
fortuitous observation suggests a possible link between this drug and the recovery of the CO2 
chemosensitivity. Additionally, recent findings indicate that multiple structures in rodent brain 
(including some structures Phox2b positive in adulthood) are activated by desogestrel 
suggesting their hypothetical role in the recovery observed in the two CCHS patients (Joubert 
et al., 2016; Loiseau et al., 2014). However, the molecular mechanism of desogestrel effect 
was so far completely unknown. 
In the first part of my PhD thesis I present the results obtained by investigating the mechanism 
underlying this effect. These results have been published in the paper “DESOGESTREL DOWN-
REGULATES PHOX2B AND ITS TARGET GENES IN PROGESTERONE RESPONSIVE 
NEUROBLASTOMA CELLS” in Experimental Cell Research (Cardani et al., 2018), and provide 
the evidence of a direct molecular link between PHOX2B and desogestrel. This finding 
suggests the possibility that this mechanism may contribute to the positive effects observed 
in the two CCHS patients. 
A strong limitation to our comprehension of the molecular mechanisms underlying CCHS and the 
development of new and effective treatment for this disease is due to the substantial lack of 
knowledge of all target genes regulated by PHOX2B and their specific involvement in the 
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different clinical manifestations of CCHS and the availability of CCHS cellular models. Specific 
genes are affected differently by distinct PHOX2B mutation (Di Lascio et al., 2016), thus 
leading to different severity of respiratory symptoms, organ involvement, request of medical 
assistance, quality of life, and probably different life expectancy in CCHS patients. Since 
PHOX2B is an important transcriptional regulator, it is very likely to hypothesize that a general 
transcriptional dysregulation might be an important mechanism of CCHS pathogenesis. So far, 
very little is known about the genes regulated by PHOX2B; most of them are regulatory genes 
encoding for transcription factors and enzymes that control downstream processes involved 
in the survival and differentiation of specific neural structures (Lo et al., 1999; Adachi et al., 
2000; Flora et al., 2001; Borghini et al., 2006; Bachetti et al. 2005; Revet et al., 2008; 
Nagashimada et al., 2012; Bachetti et al., 2010; Cargin et al., 2005). 
The possibility of improving ventilatory and sensory responses to hypercapnia upon progestinic 
treatment emphasizes the importance of identifying new PHOX2B target genes that can be 
deregulated in the pathology. Finding additional PHOX2B target genes is important not only 
for explaining the pathogenetic mechanisms underlying the dysfunctions of specific neural 
structure, but especially because they might be potential targets, alternative to PHOX2B, for 
pharmacological interventions in order to develop alternative molecules, without 
contraceptive effect, that can be also chronically administered to mail patients.  
For this reason, in the second part of my PhD project I will show results on the identification of 
some of the relevant PHOX2B target genes, whose deregulation is eventually responsible for 
the disease and the constellation of clinical symptoms, in the perspective of rescuing their 
normal activity and ameliorate breathing and dys-autonomic CCHS symptoms, also by-passing 
PHOX2B mutations.  
Previous studies, conducted in our laboratory, by means of ChIP-seq experiment identified many 
PHOX2B target gene candidates (around 3000 genes) consistent with PHOX2B role during ANS 
development and maintenance that need to be validated. Interesting, among these predictive 
genes, there were several genes encoding for K+ and Na+ channels. Several findings 
demonstrated that many of them are involved in the regulation of the excitability of 
autonomic neurons and in the modulation of respiratory activity in vivo (Mulkey et al., 2015; 
Torrecilla et al., 2013; Bond et al., 2000) suggesting that their expression could be 
deregulated in CCHS patient, and they represent potential therapeutic target for the 
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treatment of respiratory dysfunction. I focused my attention on this promising category.  
By means of stable IMR32 cell clones, where the expression of PHOX2B has been knocked-down 
by means of CRISPR-Cas9 editing technology, I will show that the expression of three K+ 
channels (KCNN3, KCNMA1 and KCNQ5) and four Na+ channels (SCN2A, SCN3A, SCN8A and 
SCN9A) is up-regulated in the absence of PHOX2B, thus suggesting a negative modulation of 
their expression by PHOX2B. Moreover, transient expression of PHOX2B +7 and +13 Alanine 
mutant proteins showed an up-regulation of the expression of KCNN3 gene, thus suggesting 
that the mutant proteins acts as inducer of this gene (gain of function mechanism).  
Since ion channels are the primary determinants of neuronal cell excitability and in PHOX2B 
knockout (KO) IMR32 clone their expression was up-regulated, in collaboration with Flavia 
Antonucci (University of Milan) I investigated whether this deregulation impairs the 
electrophysiological properties of the cells. We tested ion channels activity in PHOX2B KO and 
control cells by measuring total ion currents induced by injection of hyper-to-depolarizing 
currents. Preliminary data demonstrated that PHOX2B KO cells are more polarized than 
control, thus leading us to hypothesize that these cells might be less prone to respond to 
activating stimuli. 
These data suggest that de-regulation of the expression of genes important for the correct 
response of neuronal cells to stimulatory signals, such as response to increase CO2 levels, 
might be one of the mechanisms underlying CCHS pathogenesis. Consequently, these genes 
represent suitable candidates for pharmacological intervention in CCHS that aims to restore 
their correct expression to ensure a correct function of the neurons in the central and 
peripheral chemoreceptors. 
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CCHS is considered a life-long disorder. Until now, no pharmacological treatment has yet provided 
to be capable of restoring the normal ventilation in patients; for this reason, the only 
available support for CCHS affected patients is the mechanical ventilation by means of nasal 
masks, tracheotomy, or phrenic nerve stimulation through diaphragmatic pacemaker 
implantation. The absence of adequate treatments can result in central hypoxia with 
consequent risks of neurological damages, and fatal consequences. 
The aim of current CCHS treatment research is to counteract the toxic effect of PHOX2B mutant 
protein; drugs promoting the refolding and/or clearance of mutant protein aggregates have 
provided to be effective in rescuing the nuclear localisation and transactivation activity of 
mutant proteins in vitro (Di Zanni et al., 2012; Bachetti et al., 2007; Trochet et al., 2005). 
Recently, a new pharmacological perspective arose from the observation that two female patients 
with +5 and +6 Alanine expansion showed a partial recovery of the ventilatory response to 
CO2 and increased ventilation after treatment with the oral contraceptive desogestrel (Straus 
et al., 2010). 
The molecular mechanism underlying this effect is unknown. Recent data suggests that multiple 
pathways are involved in the ventilatory effect mediated by desogestrel (Loiseau et al., 2014; 
Joubert et al., 2016) and, in addition, experiments on adult rodent brain have revealed that 
some regions, including some phox2b+, are activated by desogestrel, thus suggesting a 
possible link between PHOX2B and desogestrel. 
Since it was reported that neurons, that play a central role in CO2 chemosensitivity, co-express 
PHOX2B and PGR (Kang et al., 2007; Quadros et al., 2008) we investigated whether there was 
a relationship between Pg and PHOX2B activity and in particular, whether desogestrel was 
able to affect the expression of PHOX2B and its target genes.  
Preliminary data collected in my laboratory on T47D human breast adenocarcinoma cell line, 
provided us the first evidence that 3-ketodesogestrel (3-KDG), the active metabolite of 
desogestrel, is able to influence the activity of PHOX2B, by the activation of the intracellular 
PGR. 
In order to further investigate the desogestrel mechanism in a cellular background more properly 
associated with the physiological PHOX2B environment, we used SK-N-BE(2)C neuroblastoma 
cell line that express high level of PHOX2B but low level of PGR. 
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In these cells, transiently transfected with PGR and treated with 3-KDG, we showed a reduction in 
PHOX2B protein level and a decrease activity of two known PHOX2B target genes (TLX2 and 
DBH) thus confirming the existence of a relationship between PHOX2B activity and 
desogestrel. 
To further investigate this relationship, we generated SK-N-BE(2)C cell clones, stably expressing 
PRG isoforms B and A. Among the generated clones, we chose two clones that express 
differently the two PGR isoforms and in this cellular model we analysed the effect of 3-KDG 
treatments on endogenous PHOX2B protein amount and transcription levels by using western 
blot and qRT-PCR analyses.  
Our findings demonstrated the existence of a direct molecular link between desogestrel and the 
expression of PHOX2B and in particular, our data showed that: 
• 3-KDG down-regulates endogenous PHOX2B protein; 
• 3-KDG reduces the protein level of some direct PHOX2B target gene (DBH and TFP2A) 
whereas genes not regulated by PHOX2B are not affected (SP1, CREB and c-JUN) 
• 3-KDG partially affects PHOX2B mRNA degradation but does not affect PHOX2B protein 
stability; 
• 3-KDG down-regulates mutant PHOX2B (+7 Ala) protein  
Our data provide the evidence that the biologically active metabolite of desogestrel, 3-KDG, 
directly affects PHOX2B gene expression and its target genes, as well as mutant protein by 
reducing their expression. This specific effect on the PHOX2B pathway is mediated through 
PGR-B by a post-transcriptional mechanism. Our results open up the possibility that the 
down-regulation of PHOX2B mutant proteins may contribute to the recovery of CO2 sensitivity 
observed in the two CCHS patients. However, further research is necessary to evaluate the 
benefit of pharmacological approaches that reduces the expression of both the mutant and 
the WT proteins in CCHS patients. 
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Fig.6 3-KDG has a specific effect on the PHOX2B pathway. Schematic representation of 3-KDG effects on endogenous 
protein and transcription levels. A) 3-KDG treatment down-regulates endogenous PHOX2B protein level up to 20% 
whereas reduces PHOX2B mRNA by no more than 50%. B) 3-KDG reduces the expression of some of PHOX2B target 
genes (DBH and AP2α) with two different kinetics in the two clones, that express different level of PGR-B, and the 
promoter activity of TLX2 in SK-N-BE(2)C cells transiently transfected with PGR.  
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Part 2 
 
Preliminary data 
 
In order to identify new PHOX2B target genes we took advantage of a genome-wide approach. 
Cross-linked chromatin from IMR32 was immunoprecipitated by means of PHOX2B antibody 
(Cargnin et al. 2005) followed by massive parallel sequencing of the co-immunoprecipitated 
genomic DNA fragments (ChIP-seq). We used, as starting material, human neuroblastoma cell 
line IMR32, which is a universally accepted model of neural crest derivative. Moreover, IMR32 
cell line shows most of the molecular features of a sympathetic ganglionic cell, a kind of 
structure heavily affected in knockout mice, with the advantage of unlimited amounts of 
homogeneous material. Immune-precipitated chromatin and input DNAs were sequenced by 
means of the 5500 W Series Genetic Analysis Systems, SOLiD® (Applied Biosystems), in 
collaboration with Genomnia, s.r.l. The sequencing generated a data set of approximately 60 
million mapped reads for both samples. MACS software has been applied to identify PHOX2B-
binding enriched regions. To determine genomic location, a total of 8512 peaks 
corresponding to approximately 3000 genes, were detected and were mapped to RefSeq 
genes (UCSC Genome Browser (GRCh37/h19, February 2009). The distance of each peak to 
the nearest transcription start site (TSS) was analysed and plotted, revealing a significant 
enrichment of PHOX2B-binding sites around genes TSS (Fig.7A). The analysis of peaks 
distribution demonstrates that 48.9% of PHOX2B-binding sites were located 5' of its regulated 
genes, 34% were mapped to the intergenic regions downstream to a known gene and the 
remaining binding sites (16.86%) were found internal to known genes (introns or exons) 
(Fig.7B). The search for enriched motifs within the PHOX2B-binding sites revealed, in more 
than 50% of the peaks, a sequence element containing an inverted arrangement of two 
consensus motifs for homeodomain proteins (ATTA sequence). This is compatible with the 
binding properties shown by other paired-type homeodomain transcription factors, which 
have exhibited cooperative interactions between two closely spaced binding sites (Fig.7C).  
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Fig.7 Genome-wide distribution of PHOX2B binding sites in human neuroblastoma IMR32 cell line. A: the graph 
shows the distribution of peaks obtained by ChIP-seq analysis relative to TSS. B: genomic distribution of PHOX2B-
binding sites relative to human RefSeq genes (GRCh37/hg19, February 2009). Location analysis of peaks for PHOX2B 
relative to TSS shows that most PHOX2B-binding regions are enriched upstream its regulated target genes. C) PHOX2B 
recognition motif predicted using data from ChIP-seq experiments.  
 
 
Gene Ontology (GO) analysis of the set of peak-associated genes have identified several enriched 
terms consistent with PHOX2B role during ANS development and maintenance, such as 
synaptic transmission, regulation of embryonic development, cell-cell signalling, 
axonogenesis, and neuron development. A further functional annotation clustering by 
Reactome (Fabregat et al., 2016; Milacic et al., 2012) revealed pathways that were associated 
with axon guidance, signal transduction, neuronal system and neuronal transmission (Tab.1), 
among which potassium ion channels. 
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Tab.1 Functional annotation clustering performed by Reactome revealed clusters associated with the indicated 
terms. The first 20 significant pathways are listed. Included genes have been previously sorted by GO analysis 
(Biological Process). 
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Material and methods 
 
Cell cultures 
 
The human neuroblastoma cell line IMR32 was grown in RPMI 1640 medium, 100 units/mL 
penicillin, 100 mg/mL streptomycin, 2 mM L-glutamine (LONZA), supplemented with 10% 
foetal bovine serum (FBS, Euroclone). The IMR32 6.4 stable clone was maintained under 
selection by adding Puromycin dihydrocloride (SIGMA-ALDRICH) at 0.06 μg/mL final 
concentration, with selective medium changing every second day. All cell lines grow in 
adhesion incubated at 37°C in the presence of 5% CO2. 
 
CRISPR/Cas9 knock-out IMR32 cells generation. 
 
Stable PHOX2B KO in IMR32 cells were generated by CRISPR/Cas9 technology. Three different 
gRNAs were designed to target the exon 1 of PHOX2B (PHOX2B-A: 3’ 
GCAGGAACTGAAGTCAGCAT 5’, PHOX2B-B 3’ GCTGCAGGATCCCFGGCGTGA 5’ and PHOX2B-C 
3’ CATACAGGACTCGTAGGCAG 5’) and cloned in transEDIT gRNA plus Cas9 (pCLIP-All) vector 
(transOMIC) implemented with a puromycin resistance gene.  The transEDIT pCLIP-All 
negative control was used as empty vector containing a gRNA with no target sequence (SCR: 
3’ GGAGCGCACCATCTTCTTCA 5’).  
Cleavage detection assay was performed by means of GeneArt™ Genomic Cleavage Detection Kit 
(Life technologies) after transfection of gRNAs. In particular, 1x106 IMR32 cell line were plated 
in 60 cm plate and transfected with 1 µg of PHOX2B gRNA plasmid and 3 µL of Lipofectamine 
3000/plate (Invitrogen). Cells were also transfected with the empty vector as a control. 
Seventy-two hours post transfection, transfected cells were selected by using 0.250 µg/ml 
puromycin for five days. Cells were harvested, and genomic DNA was extracted (Cell Lysis 
buffer/Protein Degrader, Invitrogen). A region of exon 1 of the PHOX2B gene was amplified 
with specific primers (forward primer: 5’ GCTCGGTGCGTATGGTGTGGTA 3’; reverse primer: 5’ 
TCAGAAAGTTGACCCAACTC 3’). Homoduplex PCR products were denatured and rehybridized 
using step down annealing conditions to generate homo- and hetero-duplex. The mixture of 
duplexes was treated with the Detection Enzyme for 1 hour at 37°C (Life technologies) and 
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the samples were then analysed on 2% agarose gel and stained in ethidium bromide solution 
(0.5 µg/mL). For each sample was included a no enzyme control. The relative proportion of 
cleaved DNA contained in each band was determined using UVITEC Cambridge 
transilluminator and UVI-1D analysis software. The cleavage efficiency was calculated as the 
percentage of cleaved bands with respect to total amplificated DNA (parental plus cleaved 
bans).  
Before stable transfection, pCLIP-All vectors containing gRNA -A, -B and SCR were linearized by 
incubation with restriction enzyme SmaI (New England BioLabs). 30 units of enzyme were 
used to cleave 10 µg of DNA in 25°C for 2 hours. The cut DNA was analyzed by 0.8% agarose 
gel and stained in ethidium bromide solution (0.5 µg/mL).  
One day before transfection 1x106 IMR32 cells were plated in 100 mm dishes in RPMI  1640 
medium devoid of antibiotics and transfected with 5 µg of transOMIC vector in a ratio of 1 
DNA: 3 LipofectamineTM 3000 (invitrogen). 48 hours post-transfection cells were diluted to a 
final concentration of 1X106 IMR32 cells/dish and selected by the addition of puromycin 0.250 
µg/mL to the culture medium. Selective medium was changed every second day and after 
around twenty days individual colonies were picked up and transferred to multi-well plates 
for further propagation. Selected clones were screened by immunoblotting with PHOX2B 
antibodies and hypothetical knockout clones were analysed by sanger sequence. 
 
Chromatin Immunoprecipitation  
 
The chromatin immunoprecipitation assay was performed as those presented in Preliminary data. 
The day before fixation and immunoprecipitation, IMR32 cells were plated in 10 cm dishes in order 
to reach a density of 1 x 107 cells/petri dishes, and the chromatin immunoprecipitation 
performed as described below.  
The day after plating, IMR32 cells were cross-linked with 1% final formaldeyde solution (SIGMA-
ALDRICH) for 10 minutes at room temperature and neutralized with 0.125 M glycine for 5 
minutes. The cells were then washed twice with cold PBS 1X and collected by centrifugation 
at 3000 rpm at 4°C for 2 minutes. 2 x 107 IMR32 cells were then washed twice by repeated 
resuspension in 1 mL of Cell Lysis Buffer (Hepes 5mM, KCl 85 mM and Triton X-100 5%) added 
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with 1 mM PMSF and protease inhibitor 100X and, kept 5 minutes on ice, followed by 
centrifugation at 3000 rpm at 4°C for 2 minutes. The pellet was then resuspended in 500 μL of 
Nuclei Lysis Buffer (Tris HCl pH 8 50 mM, EDTA 10 mM, SDS 1%) added with 1 mM PMSF and 
protease inhibitor 100X and the lysate was sonicated in order to obtain chromatin fragments 
of about 200 nucleotides.  
100 μL of sonicated lysate were then diluted 1:5 in 400 μL Dilution Buffer (SDS 0.01%, Triton X-100 
1.1%, EDTA 1.2 mM, Tris HCl pH 8 16.7 mM, NaCl 167 mM) and 5 μL of the chromatin was 
removed and saved as “Input 1%.” Before to add Novex rProtein G Agarose beads (Life 
Technologies) to sonicated chromatin, 200 μL of Novex rProtein G Agarose beads were pre-
cleared three times in PBS 1X and centrifuged at 3000 rpm at 4°C for 30 seconds and then 
resuspended in 400 µL ChIP Dilution Buffer. The beads were then added to the sonicated 
chromatin, diluted with 1.2 mL of ChIP Dilution Buffer, and pre-cleared for 1 hours at 4°C on 
rotation wheel. 500 μL of the pre-cleared chromatin was added in 1.5 mL tubes together with 
5 μg of appropriate antibodies: anti-hPHOX2A and anti-hPHOX2B antibodies (Davids 
Biotechnologie, Ragensburg, Germany) (Cargnin et al., 2005) and anti-PHOX2B (B-11) (Santa 
Cruz, Oregon, USA) or with non-specific Rabbit IgG (Santa Cruz, Oregon, USA) or Chicken IgY 
(Davids Biotechnologie, Ragensburg, Germany) as control. The chromatin and the antibodies 
were then incubated over night at 4°C on rotation wheel. 
100 μL of pre-coated beads were added to the chromatin samples and incubated for 4 hours at 
4°C on rotation wheel. The following steps consisted in four 10 minutes washes at 4°C with 
ChIP Dilution Buffer, Dialysis Buffer (EDTA 2 mM, Tris HCl pH8 50 mM, N-lauryl sarkosyl 0.2%), 
TSE-500 (SDS 0,1%, EDTA 2 mM, Triton X-100 1%, Tris HCl pH8 20 mM, NaCl 500 mM) and LiCL 
Buffer (LiCl 500 mM, Deoxycholic Na 1%, Triton X-100 1%, Tris HCl pH8 100 mM) and two 5 
minutes washes with TE (Tris HCl pH8 10 mM, EDTA 1mM). The beads were then eluted twice 
in 50 μL of Elution Buffer (NaHCO3 50mM, SDS 1%) and incubated for 15 minutes on rotation 
wheel; 6.6 μL of NaCl 5M was added and DNA de-crosslinked by over-night incubation at 
65°C.  
The DNA was then purified using the Chromatin IP DNA Purification kit (Active Motif) and the 
quantification of the precipitated DNA was done using SYBR-Green based qRT-PCR assay using 
the ABI Prism Thermocycler (QuantStudio 5, Applied Biosystems, CA). The DNA sample were 
heated to 50°C for 2 minutes and then to 95°C for 10 minutes, followed by 40 cycles of 
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heating to 95°C for 15 seconds, and combined annealing/extension at 60°C for 1 minute.  
ChIP specific primers used in the studies are provided in table 2. Primers for the PHOX2B promoter 
region (Cargnin et al., 2005) were used as positive control for the ChIP. 
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Name Sequence 
PHOX2B promoter ChiP NEW FW 5’-GCT CGG TGC GTA ATG GTG TGG TA-3’ 
PHOX2B promoter ChiP NEW REV2 5’-GGT TGG TCT TAT TGC TGG CGC TT-3’ 
KCNJ16 peak 6100 FW 5’-TTT GGG GAG CAG CAA CAC T -3’ 
KCNJ16 peak 6100 REV 5’-ATG ACA CAC TGT TTG TTC CTA CT-3’ 
KCNJ16 peak 6101 FW 5’-CAC ATA GCT AGC TTA CCT CCA GAA-3’ 
KCNJ16 peak 6101 REV 5’-ACT AGA AAT GTG ACT CCC CCA AT-3’ 
KCNJ3 peak 727 FW 5’-AGG AAT ATT CAG GCA ACA TCA CT -3’ 
KCNJ3 peak 727 FW 5’-GAC ACC ACC GGC TGT AGA AA -3’ 
KCNMA1 peak 2512 FW 5’-TGC TGG AGC ATT TAA ATC CGT TG-3’ 
KCNMA1 peak 2512 REV 5’-TCC TTT ACC AGA AAC CTC AAA AAC A-3’ 
KCNK13 peak 4859 FW 5’-CCT TGG ACA CTT GCT TAC CCT AT-3’ 
KCNK13 peak 4859 REV 5’-TTC CCA CCT AAA TTT GCC AAT GC-3’ 
KCNAB1 peak 9029 FW 5’-GGT GCT CTG AAG TCC GTA ACT AA-3’ 
KCNAB1 peak 9029 REV 5’-TCT TCA GTA AAC CAC ACC TAA ACT-3’ 
KCNN3 peak 1205 FW 5’-GGC AGG TTA TAC CAT TGT AGG CT-3’ 
KCNN3 peak 1205 REV 5’- TCC TGT CTT CTG TTC GAT CAC TG-3’ 
KCNJ6 peak 8184 FW 5’-GCT GAA GTC CTA ATC TCC GGT ATT T-3’ 
KCNJ6 peak 8184 REV 5’-GGA CTA GGG CCC ACC AGT AT-3’ 
KCND2 peak 12364 FW 5’-TCC ACT GCA GAT GTA ATA AGA ACA A-3’ 
KCND2 peak 12364 REV 5’-TCA ACT ACA TTG CAT TCA CAA AGG A-3’ 
KCNQ5 peak 11287 FW 5’-TGA TGA AAT GAG ATG ATG CCA GAT-3’ 
KCNQ5 peak 11287 REV 5’-TTA GTT ACT AGG GAC ACA GTG CT-3’ 
KCNK2 peak 2003 FW 5’-AGA AGT TGT GGT TGC TTG GC -3’ 
KCNK2 peak 2003 REV 5’-GGA TTT CAC TTT TTA CTG CAT GGT -3’ 
KCNK2 peak 2005 FW 5’-AGG CAA TTG TCC TGA GCA AAT TAA A-3’ 
KCNK2 peak 2005 REV 5’-GTT CCC ATG GAA TCT GTT TCT TCA -3’ 
KCNB2 peak 12800 FW 5’-GCT GTG ATG GAA TAT GGA GCC TA -3’ 
KCNB2 peak 12800 REV 5’-TCA ATC TTT CCC CAT TGT GAT CCT -3’ 
 
Tab.2 Sequences of the primers used in the conventional ChIP followed by SYBR-Green based qRT-PCR  
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Transient Transfections  
 
IMR32 cells and IMR32 6.4 stable clone were transiently transfected by lipofection method using 
FuGENE HD Transfection Reagent (Promega) or Lipofectamine® 3000 Transfection Reagents 
(Life Technologies). Briefly, the day before transfection 6x105 cells were plated on 6-well plate 
in 2 mL RPMI 1640 medium without antibiotics. The day of transfection 2.5 μg of plasmid DNA 
were incubated with 7.5 μL FuGene HD in a 1:3 ratio (DNA/ FuGene HD) in plain DMEM 
medium to a final volume of 200 μL. After incubation for 15 minutes at room temperature the 
mixtures are added drop-wise to the cells (200 μL/well). For the transfection with Lipo3000 
the day after plating, 7.5 μL Lipofectamine® 3000 Reagents were diluted in Opti-MEM 
Medium (Life Technologies) to a final volume of 125 μL. In a second master mix, 2.5 μg of 
plasmid DNA were incubated with 5 µL P3000 Reagents (2µl/µg DNA) and Opti-MEM Medium 
to a final volume of 125 μL.  The diluted DNA mix was added to diluted Lipofectamine® 3000 
Reagents (1:1 ratio) and incubated for 5 minutes at room temperature and added to cells 
(250 μL/ well). The final ratio between DNA and transfection reagent was 1:3. 
The plasmid constructs used were: 
• PHOX2B WT and +7Ala Myc-His: the Myc-tagged PHOX2B wild-type and +7 alanine mutant 
plasmid have been described previously (Di Lascio et al., 2018; Di Lascio et al., 2013); 
• PHOX2B WT and +7Ala V5-His: the V5 tagged PHOX2B wild-type and +7 alanine mutant 
plasmid have been described previously (Bachetti et al., 2005); 
• PHOX2A pCMV Myc-His: the Myc-tagged PHOX2A expression vector was obtained by 
cloning human PHOX2A cDNA into the EcoRI site of pCMV-Myc (Clontech) (Benfante et al., 
2007); 
• pCMV-Myc (Clontech) and pcDNA3.1TOPO/V5-His (Invitrogen): empty vectors used as 
control 
All the constructs were checked by means of restriction analysis and partial sequencing 
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Total RNA Extraction and Reverse Transcription  
 
Total RNA, from cultured cells, was extracted using the RNeasy Mini kit and accompanying 
QIAshredder (Qiagen), according to information provided by the company.  
Briefly, about 1x107 cells, grown in 100 mm dishes, were washed twice with PBS 1X (0.14 M NaCl, 
27 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4), detached mechanically and collected 
by 5 minutes centrifugation at 5000 rpm at 4 °C in an Eppendorf microcentrifuge. The cells 
were lysed with 350 μL of buffer RLT added with β-mercaptoethanol (10 μL/mL RLT buffer). 
The lysate was homogenized by means of QIAshredder column centrifuged for 2 minutes at 
maximum speed.  
To avoid DNA contamination, samples were incubated on-column with DNase I (2.73 U/uL) for 15 
minutes at room temperature and RNA eluted with 30 μL of RNase-free water. The amount of 
eluted total RNA was determined by spectrophotometer at 260 nm (1 OD260 = 40 μg/ mL) and 
its purity was evaluated using the 260/280 nm ratio (≥ 2).  
500 ng of total RNA per sample were reverse transcribed using the Go ScriptTM Reverse 
Transcriptase kit (Promega), in accordance with the manufacturer's instructions.  
Briefly, total RNA was firstly incubated at 70°C for 5 minutes with Random primers (Hexamers) 
0.5μg/ reaction and Nuclease-free water to a volume of 5 μL, and then chilled on ice for 5 
minutes. After that, each sample was added with 15 μL of a second reaction mix composed by 
Nuclease-Free Water, GoScriptTM 5X Reaction Buffer, MgCl2 (final concentration 4mM), PCR 
Nucleotide Mix (final concentration 0.5mM each dNTP), Recombinant RNasin®Ribonuclease 
Inhibitor 20 units and 200 units GoScriptTM Reverse Transcriptase. The reaction is continued at 
25 °C for 5 minutes to allow the annealing of the primers, 42 °C for 1 hour for the extension 
and 70 °C for 15 minutes for the inactivation of Reverse Transcriptase. The cDNAs of interest 
were then amplified and analysed quantitatively by Real-Time PCR.  
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Quantitative Real-Time PCR  
 
Gene expression analysis was performed by quantitative Real-Time PCR assay using the ABI Prism 
Thermocycler (QuantStudio 5, Applied Biosystems, CA). The target sequences were amplified 
from 50 ng of cDNA in the presence of TaqMan® Gene expression master mix (Life 
Technologies, Inc.) 
The TaqMan® primer and probe assays (Life Technologies, Inc.) used in the studies are provided in 
table 3. Each sample was run in triplicate, and the 2−ΔCT and the 2−ΔΔCT method were used to 
calculate the results, thus allowing the normalization of each sample to the endogenous 
control GAPDH, and comparison with the calibrator for each experiment (set to a value of 1) 
as indicated in the figure legends. Results are shown as the mean values ± standard deviation 
and the statistical analyses were made by means of one-way ANOVA, Tukey’s test or an 
unpaired two-tail student’s T-test using GraphPad Prism 5 Software (GraphPad Software, 
Inc.). P values <0.05 were considered significant. 
 
TaqMan® assay  
human PHOX2B (Paired like homeobox 2B) ID #Hs00243679_m1 
human PHOX2A (Paired like homeobox 2A) ID #Hs00605931_m1 
human DBH (Dopamine-β-hydroxylase) ID #Hs00168025_m1 
human TLX2 (T Cell Leukemia Homeobox 2) ID #Hs00740145_m1 
human ChAT (choline acetyl transferase) ID #Hs00252848_m1 
human SOX10 (SRY-related HMG-box) ID #Hs00366918_m1 
human KCNMA1 (Potassium Calcium-Activated Channel Subfamily M Alpha 1) ID #Hs01119498_m1 
human KCNN3 (Potassium Calcium-Activated Channel Subfamily N Member 3) ID #Hs01546821_m1 
human KCNQ5 (Potassium Voltage-Gate Channel Subfamily Q Member 5) ID #Hs01068536_m1 
human SCN2A (Sodium Voltage-Gate Channel Alpha Subunit 2) ID #Hs00221379_m1 
human SCN3A (Sodium Voltage-Gate Channel Alpha Subunit 3) ID #Hs00366902_m1 
human SCN8A (Sodium Voltage-Gate Channel Alpha Subunit 8) ID #Hs00274075_m1 
human SCN9A (Sodium Voltage-Gate Channel Alpha Subunit 9) ID #Hs01076699_m1 
human GADPH (glyceraldehyde-3 phosphate dehydrogenase) ID #Hs99999905_m1 
 
Tab.3 TaqMan assays used in qRT-PCR  
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Total protein extraction  
 
Total protein extraction was prepared from sub-confluent cells grown in 100 mm Petri dishes 
using the freeze and thaw method.  
Briefly, IMR32 cells were washed twice with PBS 1X, mechanically harvested and collected by 5 
minutes centrifugation at 5000 rpm at 4°C in an Eppendorf centrifuge. The pellet was 
resuspended in an appropriate volume of isotonic solution (PBS 1X, PMSF 0.2 mM, DTT 0.5 
mM, phosphatase inhibitors (Cocktail I, Sigma) and protease inhibitors (Cocktail II, Sigma)). 
The cells were kept in solution for 10 minutes on ice and lysed by three cycles of 5 minutes in 
liquid nitrogen and 5 minutes in a thermal bath at 37 ° C, to obtain complete cell lysis.  
NaCl 420 mM was added drop-wise to the lysate in order to extract the nuclear proteins. After 30 
minutes of incubation at 4°C on a slowly turning rotating wheel, the extract was clarified by 
centrifugation at 13000 rpm for 30 minutes at 4°C.  
Finally, the supernatant was aliquoted, quickly frozen in liquid nitrogen and stored at -80°C; the 
concentration was evaluated using the Bradford method (Bradford, 1976). 
 
 
SDS-PAGE and Western blot  
 
20 μg proteins extract from native IMR32 cells and PHOX2B KO clone were analysed by means of 
Western blot as previously described (Benfante et al. 2008). Protein extract were separated 
on an 8%, 10% and 12% denaturing polyacrylamide gel, depending on the dimension of 
protein to be analysed, in the presence of 0.1% SDS extract (sodium dodecyl sulphate). 
Before loading, each sample was added with Laemmli loading solution (Tris-HCl pH 8.5 20Mm, SDS 
2%, β-mercaptoethanol 3%, glycerol 8%, bromophenol blue 0.03%) and denatured at 100°C 
for 5 minutes. A standard molecular weight (PageRulerTM Broad Range Unstained Protein 
Ladder, Thermo-Fisher Scientific) was loaded in parallel.  
After gel separation at 25 mA in Tris-glycine (Trizma base 25 mM, Glycine 192 mM, SDS 0.1%), the 
proteins were transferred to nitrocellulose membranes (Amersham) by electroblotting at 30V 
over-night in transfer buffer (Trizma base 25 mM, Glycine 192 mM, MetOH 20%). To control 
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the transfer, the membrane was then stained with Ponceau S, washed with distilled H2O and 
saturated with blocking buffer (non-fat milk 5%, Tris-HCl pH 7.5 20 mM, NaCl 150 mM, 
Tween-20 0.1%) for at least 1 hour.  
After blocking, appropriate primary antibody diluted in blocking buffer was added to the 
membrane and incubated for 2 hours, or over-night, depending on the manufacturer’s 
instructions. Excess of primary antibodies was removed with three washes with blocking 
buffer (5 minutes each), and the membrane was incubated in the presence of the secondary 
antibody conjugated with horseradish peroxidase, diluted in blocking solution for 1 hour. The 
antibodies used in Western blot experiments are reported in table 4. 
 The excess of antibody was then removed by different washes for 5 minutes each: two washes 
with blocking buffer; three washes in TS 1X (Tris-HCl pH 7.520 mM, NaCl 150 mM) + Tween-20 
0,1%; three washes in TS 1X + Tween-20 0.3 % and three final washes in TS 1X.  
After washes, the bands were revealed using Super Signal west Dura (Thermo Fisher Scientific) and 
the signal detected by Hyperfilm ECL film (GE Healthcare) or by ChemiDoc™ Imaging System 
(Bio-Rad) at different time exposures. 
 Densitometric analysis of the obtained signals was carried out using NIH ImageJ 1.61/ fat, or 
ImageLab software 6.0 and the results are shown as the mean values ± standard deviation.  
The statistical analyses were made by means of one-way ANOVA, Tukey’s test or an unpaired two-
tail student’s t-test using GraphPad Prism 5 Software (GraphPad Software, Inc.) as indicated in 
the figure legends. P values <0.05 were considered significant. 
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Primary antibody dilution 
PHOX2B B-11: sc-376997 mouse mAb (Santa Cruz Biotechnology) N-terminal 1:10000 
anti-hPHOX2B antibodies chicken (Davids Biotechnologie) * C-terminal 1:400 
PHOX2A Ab chicken (Davids Biotechnologie) * 1:1000 
β-Tubulin (D3U1W) mouse mAb (Cell Signalling Technology)  1:1000 
Monoclonal anti-actin Clone AC-40 (Sigma-Aldrich) 1:1000 
Sox10 (D5V9L) Rabbit mAb (Cell Signaling) 1:1000 
β3 tubulin (D71G9) XP Rabbit mAb (Cell Signaling) * 1:1000 
Dopamine-β-Hydroxilase (DBH) (N-Terminal) sheep mAb (Sigma-Aldrich) 1:500 
Goat anti-choline acetyltransferase (ChAT) Affinity purified polyclonal antibody 
 (Chemicon International) * 
1:500 
Synaptotagmin 1 105 011 Monoclonal mouse purified IgG (Synaptic Systems) 1:1000 
Monoclonal anti-syntaxin clone HPC-1 Mouse Ascites Fluid (Sigma-Aldrich) 1:1000 
 
Secondary antibody dilution 
Stabilized Goat anti-mouse HRP-conjugated (Pierce) 1:10000 
Stabilized Goat anti-rabbit HRP-conjugated (Pierce) 1:10000 
Rabbit Ab against chicken IgG-HRP (Davids Biotechnologie) 1:100000 
Donkey Ab against sheep IgG-HRP (Abcam) 1:5000 
Anti-goat IgG (WHOLE MOLECULE) peroxidase conjugate (Sigma-Aldrich) 1:10000 
 
Tab.4 Primary and secondary antibodies used in Western blot with the appropriate dilutions. *indicates antibodies 
incubated over-night according to manufacturer instruction. 
 
 
 
 
 
 
 
 
 
 47 
 
Results  
 
Validation of the binding of PHOX2B to the region corresponding to the 
peaks associated with genes that encode for potassium channels. 
 
The ChIP-seq experiment carried out previously in the laboratory, has allowed us to identify many 
PHOX2B target gene candidates that need to be validated by means of biochemical and 
functional approaches. Interestingly, among the predicted genes (approximately 3000 genes), 
there were several encodings for ionic channels (Tab.5), including seventeen selective for K+, 
belonging to four different families, and four selective for Na+ ions (two families).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tab.5 List of genes obtained from ChIP-seq analysis. A: genes encoding potassium channels are divided in four 
different families. B: genes encoding sodium channels. In red, genes expressed in IMR32 cell lines are highlighted.  
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Since several findings suggest that many ion channels are involved in the regulation of the 
excitability of autonomic neurons and in the modulation of respiratory activity in vivo (Bond 
at al., 2000; Torrecilla et al., 2013; Mulkey et al., 2015) I focused my study on this category 
and started the validation by verifying the binding of PHOX2B to those regions corresponding 
to the peaks associated with these genes. 
Specific oligonucleotides have been designed and conventional ChIP assay followed by SYBR-Green 
based qRT-PCR has been carried out. IMR32 cells were fixed with 1% formaldehyde solution 
in order to generate a reversible protein-DNA cross-link that “preserves” the protein-DNA 
interactions occurring in the cell. Cells were then lysed, and chromatin was fragmented by 
means of sonication to obtain fragments of about 200 nucleotides. The chromatin fragments 
were then immunoprecipitated using the appropriate PHOX2B antibody already used in 
ChIP-seq analysis (Cargnin et al., 2005) or with no specific antibody. After 
immunoprecipitation, the protein-DNA cross-links were reversed by over-night incubation at 
65°C and the DNA was purified by means of Chromatin IP DNA Purification kit (Active Motif). 
SYBR-Green based qRT-PCR with specific oligonucleotides for region corresponding to 
potassium channels (Tab.2), was used to measure the abundance of these specific DNA 
sequences enriched by a protein-specific immunoprecipitation versus immunoprecipitation 
with a non-specific antibody control (Fig. 8 black bars vs white bars). A ChIP positive control 
corresponding to PHOX2B promoter was included (Fig. 8, CTRL region). Figure 8 shows the 
quantification of the level of enrichment of the specific PHOX2B-binding regions (black bars) 
and the non-specific control (white bars) relative to the total amount of input DNA 
(percentage of input). The antibody directed versus PHOX2B is capable of 
immunoprecipitating the regions corresponding to potassium channels while no 
amplification products were observed using no specific antibodies. 100% of the analysed 
regions (14 in total) were found to display abundant occupancy of PHOX2B thus confirming 
ChIP-seq results. 
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Fig. 8 Validation of ChIP-seq binding sites by single gene ChIP-PCR. Conventional ChIP experiments were performed 
using PHOX2B (black bars) and IgY (PI, white bars) antibodies followed by qRT-PCR using oligonucleotides specific for 
the peaks associated with the indicated gene. 14 out of 17 sites have been validated. A positive control region 
corresponding to PHOX2B promoter region was included. The chromatin was amplified by means of SYBR-Green 
chemistry and expressed as a percentage of the input DNA ± SEM. 
 
 
 
 
As PHOX2A, the PHOX2B paralogue gene product, has in common with PHOX2B two known target 
genes (DBH and TLX2), I investigated whether it was able also to bind to the identified peaks 
and therefore regulate potassium channels. The experiment was performed as previously 
described with a specific antibody directed versus PHOX2A. I investigated six out of fourteen 
peak-associated potassium channel genes. A positive control region was included (Fig. 9, CTRL 
region). Remarkably, the antibodies directed against PHOX2A were also able to 
immunoprecipitate the same regions (Fig. 9 black bars), thus suggesting that this transcription 
factor might also participate in the transcriptional regulation of potassium channels. 
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Fig.9 PHOX2A binds region corresponding to genes encoding for potassium channels. Conventional ChIP experiments 
were performed using PHOX2A (black bars) and IgY (PI, white bars) antibodies followed by qRT-PCR, using 
oligonucleotides specific for the peaks associated with the indicated gene. Six peaks have been validated. A positive 
control region (PHOX2B promoter) was included. The chromatin was amplified by means of SYBR-Green chemistry and 
expressed as a percentage of the input DNA ± SEM. 
 
 
 
To further validate ChIP-seq results, another single gene ChIP-PCR was performed. In two parallel 
experiments, chromatin fragments were immunoprecipitated with a new PHOX2B antibody 
(Phox2b (B-11) mouse mAb) and with anti-PHOX2A antibody as control (Fig. 10 black and 
white bars, respectively). As ChIP positive control, the amplification of the region 
corresponding to PHOX2B promoter was included (Fig. 10, CTRL region). Quantification of the 
precipitated DNA, expressed as percentage relative to the INPUT showed that specific 
amplification was observed using PHOX2B and PHOX2A antibodies in 100% of the analysed 
peaks, while no amplification was detected using IgY (white bars), thus confirming previous 
results.  
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Fig.10 PHOX2B and PHOX2A bind region corresponding to encoding gene for potassium channels. Conventional ChIP 
experiments were performed using PHOX2A (black bars), PHOX2B (grey bars) and IgY (PI, white bars) antibodies 
followed by qRT-PCR using oligonucleotides specific for the peaks associated with the indicated gene. Six sites have 
been validated. A positive control region (PHOX2B promoter) was included. The chromatin was amplified by means of 
SYBR-Green chemistry and expressed as a percentage of the input DNA. 
 
 
These data, obtained by using two different antibodies directed versus PHOX2B, also confirmed 
the specificity of the interaction of PHOX2B with the regions corresponding to the peaks 
identified by ChIP-seq analysis in potassium channels genes, and again we demonstrated that 
some of potassium channels encoding genes might be co-regulated by PHOX2B and PHOX2A. 
 
Generation of PHOX2B knockout cell lines 
  
To study the role of PHOX2B on ion channels encoding-genes expression, I generated a stable 
PHOX2B KO cell model, by means of CRISPR-Cas9 editing technology. Clustered regularly 
interspaced short palindromic repeats (CRISPR)/Cas system is an RNA-programmable host 
defence mechanism in bacteria and archaea that degrade foreign nucleic acid to protect them 
against invading virus and bacteriophages (Hsu et al., 2014). The type II CRISPR system, found 
in S. pyogenes, has been engineered to edit genes in mammalian cells (Jinek et al., 2013) by 
fusing the essential non-coding RNA components of the CRISPR locus into a single guide RNA 
(gRNA). The 5’-end of gRNA could be programmed with a 20-bp guide sequence that will bind 
to its complementary genomic target through Watson-Crick base pairing while the 3’-end is 
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associated with the Cas9 enzyme. The target sequence is always followed by a proto-spacer 
adjacent motif (PAM) that corresponds to a trinucleotide sequence “NGG”, where N can be 
any nucleotide. At the level of its target site the Cas9 nuclease generates a double stranded 
break (DSB) near the PAM that induces DNA repair mechanisms such as non-homologous end 
joining (NHEJ), leading to formation of nucleotide insertion or deletion “indels” (Fig.11) 
causing frameshift mutation of the ORF, with the possibility to create a stop codon with the 
premature termination of protein synthesis (Ran et al. 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.11 Schematic representation of CRISPR-Cas9 system. The Cas9 nuclease from S. pyogenes (brown) is targeted to 
genomic DNA by a gRNA consisting of a 20-nt guide sequence (green) and a scaffold (grey). The guide sequence pairs 
with the DNA target (green sequence on dsDNA), directly upstream of a requisite 5′-NGG adjacent motif (PAM; red). 
Cas9 mediates a DSB ~3 bp upstream of the PAM (black triangle) that can be repaired in the error-prone NHEJ 
pathway with the generation of random insertion/deletion (indel; yellow) mutations at the site of junction. Indel 
mutations occurring within the coding region of a gene can result in frameshifts and the creation of a premature stop 
codon, resulting in gene knockout. Modify from NEW ENGLAND BioLabs.inc 
 
 
 
 
To selectively knock out PHOX2B expression from cells that natively expresses it (IMR32 
neuroblastoma cell lines) I first had to identify an appropriate target site in PHOX2B encoding 
sequence for gene editing. In order to avoid off target effects, the site was selected outside 
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the HD encoding region, which show a very high homology with other homeobox protein 
(Yokoyama et al., 1999). Despite PHOX2B and PHOX2A show 56.4% homology in exon1 
encoding sequence, I focused on this exon as a putative target site, because NHEJ-mediated 
frameshift within this region could potentially terminate translation upstream the HD, that 
contain the DNA-binding site for target gene promoter, thus eliminating PHOX2B 
transcriptional activity (Fig.12C). 
Three different candidates 20-bp gRNAs, named PHOX2B-A, PHOX2B-B and PHOX2B-C positioned 
immediately 5’ to the trinucleotide PAM sequence on the minus strand of the PHOX2B gene 
(Fig.12B) have been chosen. They were cloned into transEDIT gRNA plus Cas9 (pCLIP-All) 
vector (transOMIC) that contains in the same vector the Cas9 gene and the human 
cytomegalovirus promoter hCMV implemented with a puromycin resistance gene (Fig.12A) 
that allows a single transfection to generate stable CRISPR clones. Moreover, as a control, we 
used a transEDIT pCLIP-All negative control empty vector containing a gRNA lacking the 
PHOX2B guide (Fig.12B; SCR). 
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Fig.12 The three PHOX2B guides RNAs and target site. A: Detailed map of transEDIT gRNA plus Cas9 (pCLIP-All) vector 
(transOMIC). The all-in-one vector contains a programmable single gRNA (light blue) and a Cas9 construct (in purple) 
in the same vector implemented with a puromycin resistance gene (in green). B: Three different sequences of the 
gRNAs directed versus exon1 of PHOX2B and a non-targeting control lacking PHOX2B guide (SCR). C top: Schematic 
representation of the PHOX2B gene and the CRISPR/Cas9 machinery. Domain structure of full-length PHOX2B. The 
location of HD (green), the NSL (blue) and the two stretches of polyalanine sequence (9 Ala and 20 Ala in black) are 
shown. The gRNA (in red) target site is located at the beginning of exon1 (target side in pink). Bottom: close-up 
representation of the three-gRNAs target sites. Immediately 3’ to the target sequence (PHOX2B-A in light blue, 
PHOX2B-B in green and PHOX2B-C in purple respectively) is the trinucleotide spacer adjacent motif (PAM in yellow). 
The Cas9 enzyme introduces a DSB near the PAM, triggering imperfect NHEJ. 
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To test the effectiveness and the specificity of the three PHOX2B gRNAs at triggering Cas9-
mediated gene editing at the target site, IMR32 cells were transiently transfected with pCLIP-
All-hCMV-Puro vector targeting different regions of the human PHOX2B locus or with the 
transEDIT pCLIP-All Negative control, resulting in the generation of a mixed population of 
edited and non-edited cells. Since IMR32 cell line shows a very low efficiency of transfection 
and we were not able to detect any cleavage efficiency on the heterogeneous pool of cells, 
seventy-two hours post transfection transfected cells were selected by the addition of 0.250 
μg/ml puromycin to the culture medium. After five days of selection, pool of cells was lysed, 
and the genomic DNA was extracted and the region containing the target site was amplified 
by PCR (primer forward: 5’ GCTCGGTGCGTAATGGTGTGGTATTA 3’, primer reverse: 5’ 
CTTCGGAACTAACGTAAACTTTT 3’). The PCR amplicons were then denatured and reannealed 
in a thermal-cycler in order to generate mismatched heteroduplex, with strands with an indel 
reannealed to strands with no indel or a different indel. These mismatches were then 
selectively detected and digested by the Detection Enzyme T7E1 (Cho et al., 2013) and the 
resultant bands were then analysed by gel electrophoresis and band densitometry. 
CRISPR/Cas9 complex trigger site generates specific DNA fragments in each sample 
transfected with the gRNAs (Fig.13 shown by a bracket) while no bands were detected in cells 
transfected with the negative control (SCR) as expected. The cleavage efficiency, reported in 
figure 13 as formation of indel, was calculated as difference between undigested band and 
the sum of the cleaved bands, expressed in percentage. Densitometry analyses showed a 
cleavage efficiency of 12.96%, 34.04% and 5.01% for the three gRNAs A, B and C, respectively. 
Since the GeneArt Genomic Cleveage Detection Kit (Life Technologies) suggested that pCLIP-
All vector containing the PHOX2B-A and PHOX2B-B gRNAs were functional and give the 
highest cleavage efficiency, we next chose them to generate clonal PHOX2B KO stable cell 
lines.  
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Fig.13 CRISPR-Cas9 mediated cleavage efficiency. Gel image of a cleavage assay using the GeneArt® Genomic 
Cleavage Detection Kit (Life Technologies). IMR32 cells were transfected with GeneArt® CRISPR All-in-one vectors 
targeting different regions of the exon1 of human PHOX2B locus (PHOX2B-A, -B and -C). A negative control sample for 
gene modification was also used (SCR). The samples were PCR amplified using the same set of primers flacking the 
region of cleavage. After re-annealing, samples were treated with (+) or without (-) Detection Enzyme and run on a 2% 
agarose gel. Treatment with the nuclease results in the generation of specific cleaved bands, shown by a bracket in 
samples transfected with All-in-one vectors while no bans were observed in cells transfected with the empty vector. 
The cleavage efficiency, expressed as formation of indel, was calculated for each sample as a difference between 
undigested band and the sum of the cleaved bans. 
 
 
 
In order to favour genomic integration of the gRNAs containing constructs in IMR32 cells, the two 
pCLIP-All plasmids and the negative control were linearized using the restriction enzyme 
SmaI, which recognizes a single site in the plasmid backbone without destroy any relevant 
sequence within construct, and transfection performed as described in Materials and 
methods section. Around 100 clones transfected with gRNA A and B and 30 clones with gRNA 
SCR were obtained and probed for PHOX2B protein expression by Western blotting analysis. 
To exclude any false negative results, two different antibodies, directed to the extreme N- 
and C- terminal ends of the protein, were used for clones obtained with gRNA-A and gRNA-B 
(Fig.14A). From this initial screening, four clones showed a complete absence of PHOX2B 
protein expression compared with the native IMR32 (Fig.14A bottom: asterisk shows clone 
A6.4 as an example), while any differences were reported between SCR clones and native 
IMR32 cells (Fig.14B). The majority of clones A and B presented specific bands, recognized by 
both antibodies, with higher or lower molecular weight than control (Fig.14A), suggesting the 
formation of insertions or deletions at the cleavage site that generate truncated or longer 
protein. 
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Fig.14. Generation of PHOX2B KO cell lines. A representative Western blot of total cell lysates from IMR32 clones 
selected with puromycin containing medium. 20 μl of cellular extract obtained from 1/3 of confluent 100 mm dish 
were separated by means of 10% SDS-PAGE and transferred to a nitrocellulose membrane. Each numbered lane 
represents one sample clone. Star indicates clone A6.4 that does not express PHOX2B protein.  Extract of the IMR32 
cell line was used as positive control of PHOX2B. β-Tubulin was used as normalizer (upper boxes). A: Anti-PHOX2B 
directed to the extreme N- and C- terminal ends of the protein were used to detect the presence of the protein 
(middle and lower boxes). Top and bottom: clones generated by the transfection of All-in-one vectors containing the 
gRNA PHOX2B-B and gRNA PHOX2B-A, respectively. B: clones generated by the transfection of All-in-one negative 
control (SCR).  
 
 
 
We decided to initially characterize one of the four obtained clones (A 6.4, Fig.15), by qPCR and 
western blotting analysis. Clone A6.4 and native IMR32 cells, used as PHOX2B positive 
control, showed comparable levels of PHOX2B mRNA (Fig.15A white bar vs black bar), 
whereas the expression of PHOX2B endogenous protein in the clone was completely absent 
(Fig.15B), as expected. 
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In order to characterize the nature of gene editing in the IMR32 6.4 clone, we PCR amplified exon 
1 from genomic DNA and the PCR product was then analysed by Sanger sequencing. Cas 9 
cleavage has generated a 10-bp deletion in clone A6.4 (Fig.15C, black arrows) that cause a 
frameshift in the ORF with consequent generation of a new amino acid sequence (10 aa, 
Fig.15C in red) and a premature stop codon (Fig.15C, showed by asterisk), resulting in no 
protein synthesis (Fig.15B). The deletion has occurred in both alleles as we were unable to 
detect any intact wild-type allele. The formation of premature stop codon and the complete 
lack of detectable PHOX2B protein expression by Western blotting with multiple PHOX2B-
specific antibodies confirmed the generation of one PHOX2B KO cell line using the 
CRISPR/Cas9 system. 
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Fig.15 Validation of PHOX2B KO clone A6.4. A: qPCR analysis of endogenous PHOX2B mRNA expression normalised to 
that of the GAPDH gene in native IMR32 (black bar) and clone A6.4 PHOX2B KO (white bar). The bars are the mean 
values ± SD (error bars) of at least three independent experiments, performed in triplicate, and are expressed as fold 
relative to IMR32 native cells (=1). The 2−ΔΔCT method was used to calculate the results. B: Left: representative western 
blot of total cell lysates from IMR32 PHOX2B KO clone A6.4 and native IMR32 as positive control of PHOX2B. 20 μl of 
cellular extract were separated by means of 10% SDS-PAGE and transferred to a nitrocellulose membrane. Actin was 
used as normalizer (upper boxes). Right: the bar chart shows the relative quantification of PHOX2B protein in clone 
A6.4 and IMR32 native cells (black bars) expressed as ratio of PHOX2B to actin. C: Sequence alignment of WT exon 1 
region (RefSeqGene human PHOX2B sequence WT) with sequences obtained from native (Control IMR32) and edited 
(cl. A6.4 K.O.) IMR32 cell lines. Clone A 6.4 lacks 10-bp at the level of cleavage site (limited by arrows). The putative 
transcription start codon ATG is underlined. The complementary plus strand sequence corresponding to the 20-nt 
target and 3-nt PAM is highlighted in yellow and blue, respectively. The WT amino acid sequence is shown above the 
nucleotide sequence and variable amino acid residues in clone A 6.4 are shown below the sequence and are 
highlighted in red. The formation of a premature stop codon is indicated by asterisk.  
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Molecular and cellular characterization of IMR32 PHOX2B KO clone 
A6.4  
 
In literature there are controversial data regarding the role of PHOX2B; some works indicated that 
PHOX2B is essential for cellular differentiation by regulating neuronal cell cycle-exit and has 
an anti-proliferative function (Dubreuil et al., 2000; Reiff et al., 2010). On the contrary, other 
studies reported PHOX2B to be an important factor for the proliferation of immature 
sympathetic neurons (Coppola et al., 2010). For these reasons, before studying PHOX2B role 
on the transcription of ion channels encoding genes, we characterized the cellular phenotype 
of the clone, to understand whether the absence of PHOX2B has changed it. 
Cell differentiation is an essential process in developmental biology and it is the result of different 
processes (differential gene expression, paused proliferation, epigenetic modifications and 
morphological changes) that convert the precursor cells to specialized ones. The 
differentiation process is ceased in certain cancer cells, but this process could be resumed 
using differentiation inducing agents; all trans retinoic acid (ATRA), for example, is one of the 
most important agents that help the cancer cell to acquire a terminally differentiated state 
(Shastry et al., 2001). 
NB is the most common extra-cranial solid tumours derived from neuronal crest cells which 
migrate and give rise to PNS, the ENS, pigment cells, Schwannian-like cells, adrenal medullary 
cells, and cells of the craniofacial skeleton. A block in differentiation program of neuronal 
crest progenitor cells causes the development of NB. 
The neuronal crest cells are multipotent, and the cell lines derived from NB, such as the IMR32 cell 
line, maintain this ability to transdifferentiate when treated with differentiation inducing 
agents. For example, Chaudhari et al. demonstrated that CDDO, a PPARγ antagonist, in 
combination with ATRA is able to induce IMR32 NB differentiation (Chaudhari et al., 2017). As 
mentioned in the introduction, it is well known that at the level of bipotential progenitors 
(Sox10+, Phox2b+) downregulation of Phox2b is a prerequisite for glial lineage differentiation 
(Sox10+, Phox2b-), whereas downregulation of Sox10 expression is necessary for neuronal 
lineage differentiation (Sox10-, Phox2b+) (see Fig.3). Moreover, it has been demonstrated that 
mutations in Phox2b gene altered the balance between the two genes in favour of Sox10 
(Nagashimada et al., 2012). For this reason, we investigated whether the absence of PHOX2B 
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in clone A6.4 would be able to cause a drastic changing in the cellular phenotype with a 
differentiation of IMR32 cells toward the glial fate (Sox10+, Phox2b-), detrimental to neuronal 
lineage differentiation. It is worth noting that during neuronal development, the down-
regulation of PHOX2B expression, at the level of neuronal precursor, is functional and 
essential to restrict cell division and allows the cells to reach a mature functional and specific 
neuronal phenotype. 
The differentiation of NB cells in vitro can be studied by changing in morphological features, as 
well as by functional criteria based on the differential expression of glial, neuronal and 
maturation markers, detected by using Western blotting and qRT-PCR analyses. PHOX2B K.O 
A6.4 stable clone was analysed at different cell passages (7, 10 and 15 days in colture) to 
detect whether the messenger and protein level expression of genes under investigation 
varied over multiple cell passages, thus suggesting a progressive differentiation to a specific 
cellular phenotype.  
Morphological differentiation of neuronal cells is defined by the appearance of one (or more) 
neuritic extension. Phase contrast images of clone A6.4 (Fig.16) showed that the complete 
absence of PHOX2B protein expression caused a changing in the cell morphology, grossly 
distinguishable from controls: clone A6.4 showed increase in neuritis length and in cellular 
body and a strong adherence to the flask surface, phenotypic changes typical of a more 
differentiated cell. 
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Fig.16 Morphological study. Cells were analysed under phase contrast microscope to study the morphological 
features of IMR32 in the absence of PHOX2B protein (right boxes) in contrast with IMR32 native cells (left boxes). The 
images were captured on a microscope equipped with a monochrome camera. High-magnification images of areas 
bounded by black boxes are shown below the corresponding low-power image. Arrows indicate increase in neurites 
length in cl A6.4.  
 
 
In order to understand the cellular phenotype of clone A6.4, we evaluated the expression of 
neuronal crest derived glial-cell lineage marker, Sox10 and the expression of neuron specific 
marker, like β3-tubulin, by qRT-PCR and by Western blot. Sox10 expression, an immature 
neural crest marker also expressed in glia cells, was not detected by RT-PCR and Western 
blotting analyses (data not shown) in both IMR32 native and in clone A6.4, thus excluding any 
change in the differentiation state of the clone towards the glial lineage. This data suggests 
that IMR32 cells, although blocked in their differentiation to sympathetic neurons, are already 
committed along neuronal lineage (Sox10-, Phox2b+) and the absence of PHOX2B at this stage 
is not sufficient to revert this process, to a more glial-differentiated stage (Sox10+; Phox2b-). 
Moreover, the expression of beta β3-tubulin, a neuron associated tubulin isotype whose 
expression is up-regulated during neuronal differentiation, was increased in clone A6.4 
compared to IMR32 native cells (Fig.17), thus confirming that the absence of PHOX2B in cl. 
A6.4 does not cause a change in the lineage specification, but on the contrary, it induces the 
cells to differentiate along the neuronal lineage and to acquire a more mature phenotype. 
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Fig.17 Expression of the neuron specific marker β3-tubulin. Top: a representative Western blot showed the 
expression of β3-tubulin (lower box) in total cell lysates from IMR32 and clones A6.4 K.O at three different cell 
passages. 20 μl of cellular extract were separated by means of 10% SDS-PAGE and transferred to a nitrocellulose 
membrane. Extract of the IMR32 cell line was used as positive control of PHOX2B. Actin was used as normalizer (upper 
box). Bottom: relative quantification of β3-tubulin protein levels in cl. A6.4 K.O at different cell passages (white 
hatched bars) and IMR32 native cells (black bars) expressed as ratio of β3-tubulin to actin. 
 
 
During differentiation of the sympatho-adrenal lineage, cells undergo a cholinergic-
catecholaminergic switch, that give raise respectively to neurons of the parasympathetic or 
sympathetic division of the ANS, depending on the target tissues they will innervate. 
Neuroblastoma cells, being blocked at earlier stage of differentiation are capable of 
expressing enzymes of both phenotypes, such as TH and DBH, adrenergic markers, and 
choline acetyl transferase (ChAT), cholinergic marker; the increase or reduction in the 
expression of these enzymes is usually used to characterize neuronal specification. Recently, 
Boeva et al. demonstrated that neuroblastoma cell lines have three types of identity and, in 
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particular, the sympathetic noradrenergic identity is further defined by the expression of 
PHOX2B, HAND2 and GATA3 (Boeva et al. 2017). In order to evaluate whether the absence of 
PHOX2B in KO clone affected the noradrenergic identity in IMR32 cell line, we studied 
PHOX2A, DBH and TLX2 mRNA and protein expression levels, three important noradrenergic 
markers. 
PHOX2A is positively regulated by PHOX2B (Flora et al., 2001) and together with PHOX2B 
cooperates to determine the noradrenergic phenotype through the induction of DBH, the 
rate-limiting enzyme in the pathway of noradrenaline synthesis (Adachi et al., 2000), and TLX2 
(Borghini et al., 2006) gene expression, a transcription factor involved in ENS development 
and mainly expressed in tissues derived from neural crest cells at the end of their migration. 
Unexpectedly, we found that the absence of PHOX2B strongly induced an increase of PHOX2A 
transcript levels by 73% (Fig.18A) in IMR32 cl. A6.4 cell line. Moreover, Western blot analysis 
showed a progressive increase in the PHOX2A protein level over multiple cell passages that 
reaches a steady-state level after seven days of culture in the KO clone compared to the WT 
(Fig.18B). As mentioned before, PHOX2A is positively regulated by PHOX2B and its 
unexpected increase in protein expression in clone A6.4 might be explained as a 
compensatory mechanism of the cells in order to maintain the noradrenergic phenotype.  
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Fig.18 Expression of PHOX2B paralogue gene, PHOX2A. A: qPCR analysis of endogenous PHOX2A mRNA expression 
normalised to that of the GAPDH gene in native IMR32 (black bar) and PHOX2B K.O clone A6.4 (white bar). The bars 
are the mean values ± SD (error bars) of at least three independent experiments, performed in triplicate. The 2−ΔCT 
method was used to calculate the results.  B Left: a representative Western blot showed the expression of PHOX2A 
(lower box) in total cell lysates from IMR32 and clone A6.4 at different cell passages. 20 μl of cellular extract were 
separated by means of 10% SDS-PAGE and transferred to a nitrocellulose membrane. Actin was used as normalizer 
(upper box). Right: relative quantification of PHOX2A protein level in cl. A6.4 at different cell passages (white hatched 
bars) and IMR32 native cells (black bars) expressed as ratio of PHOX2A to actin. 
 
 
PHOX2A co-regulates DBH and TLX2 genes; we therefore evaluated how the deletion of PHOX2B 
and the increased of PHOX2A proteins in cells affects the abundance of these two target 
genes. No changes were observed at both RNA and protein level of DBH (Fig.19A and B 
respectively) and at TLX2 mRNA level (Fig.19C) in the clone compared to native IMR32. These 
results are in agreement with what has been previously reported by Boeva et al. that the 
silencing of PHOX2B expression is not sufficient to change the noradrenergic identity in CLB-
GA and SH-SY5Y cell lines; indeed PHOX2A, HAND2, GATA3, TH and DBH are only slightly 
affected (Boeva et al. 2017). However, unlike the PHOX2B silenced cells that showed a slight 
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decrease in PHOX2A protein level, these data suggest that the maintenance of the 
noradrenergic identity in clone A6.4 might be mediated by the up-regulation of PHOX2A 
expression, with no changes in the expression of DBH and TLX2.  
 
 
 
Fig.19 Expression of the adrenergic markers DBH and TLX2. A and B: qPCR analysis of endogenous DBH and TLX2 
mRNA expression normalised to that of the GAPDH gene in native IMR32 (black bar) and PHOX2B K.O clone A6.4 
(white bar). The bars are the mean values ± SD (error bars) of at least three independent experiments, performed in 
triplicate. The 2−ΔCT method was used to calculate the results. C Left: a representative Western blot showed the 
expression of DBH (lower box) in total cell lysates from IMR32 and clones A6.4 K.O at different cell passages. 20 μl of 
cellular extract were separated by means of 10% SDS-PAGE and transferred to a nitrocellulose membrane. Actin was 
used as normalizer (upper box). Right: relative quantification of DBH protein level in cl. A6.4 at different cell passages 
(white hatched bars) and IMR32 native cells (black bars) expressed as ratio of DBH to actin.  
 
 
The increase in PHOX2A and the maintenance of DBH expression level led us to investigate 
whether the absence of PHOX2B induced any differences in the expression of ChAT an 
enzyme responsible for the synthesis of the neurotransmitter acetylcholine in 
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parasympathetic nervous system. Figure 20 shows a reduction only at protein level in clone 
A6.4 compared to control cells (Fig.20A white hatched bars vs black bar) but did not affect 
mRNA (Fig.20B). These results suggested that PHOX2B KO cell line maintains a heterogeneous 
identity leading us to hypothsize that the cholinergic-catecholaminergic switch is not 
completed yet. However, the maintenance of the expression of DBH and TLX2, the reduction 
of the expression of ChAT and the increase in expression of PHOX2A suggests that the clone 
A6.4 defective for PHOX2B expression has a tendency to differentiate into a more mature 
adrenergic neuronal lineage phenotype compared to IMR32 native cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.20 Expression of the cholinergic specific enzyme Choline acetyltransferase (ChAT). A Left: a representative 
Western blot showed the expression of ChAT (lower box) in total cell lysates from IMR32 and clone A6.4 K.O at 
different cell passages. 20 μl of cellular extract were separated by means of 10% SDS-PAGE and transferred to a 
nitrocellulose membrane. Actin was used as normalizer (upper box). Right: relative quantification of ChAT protein 
levels in cl. A6.4 at different cell passages (white hatched bars) and IMR32 native cells (black bars) expressed as ratio 
of ChAT to actin. B: qPCR analysis of endogenous ChAT mRNA expression normalised to that of the GAPDH gene in 
native IMR32 (black bar) and PHOX2B K.O clone A6.4 (white bar) and expressed according to the 2-ΔCt method.  
 
 
 
 
 
To further investigate the morphological changes induced by PHOX2B depletion, we investigated 
the protein levels of synaptotagmin and syntaxin, two vesicular markers that play an 
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important role during docking and priming vesicular process. Both markers were upregulated 
in clones A6.4 in contrast to control, suggesting a greater level of neuronal maturation 
(Fig.21).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.21 Expression of vesicular markers. Top: a representative Western blot showed the expression of synaptotagmin 
(middle box) and syntaxin (lower box) in total cell lysates from IMR32 and clones A6.4 at different cell passages. 20 μl 
of cellular extract were separated by means of 10% SDS-PAGE and transferred to a nitrocellulose membrane. Actin 
was used as normalizer (upper box). Bottom: relative quantification of synaptotagmin (right) and syntaxin (left) 
protein levels in cl. A6.4 at different cell passages (white hatched bars) and IMR32 native cells (black bars) expressed 
as ratio of synaptotagmin or syntaxin to actin. 
 
 
 
 
In conclusion, our results demonstrated that the morphological changes observed in PHOX2B KO 
cells were associated with an increase expression of neuronal markers β3-tubulin (Fig.17), 
synaptotagmin and syntaxin (Fig.21), suggesting a changing from immature neuronal 
phenotype into a mature and functional one. Moreover, the differentiation was accompanied 
by a decrease in the expression of ChAT enzyme (Fig.20) and the upregulation of PHOX2A 
(Fig.18) sufficient to maintain the noradrenergic identity (Fig.19). 
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Ion channels are new PHOX2B target genes 
 
 
Gene expression analysis of ion channels in PHOX2B knockout cell lines 
 
 
Since the absence of PHOX2B did not affect dramatically the cellular phenotype of clone A6.4 and 
the cells still maintained their adrenergic identity, we studied the transcriptional role of 
PHOX2B on ion channels by comparing their expression between this clone and IMR32 
native cells. We chose three potassium channels identified by ChIP-seq: two belong to the 
Ca2+-activated k+ channels family (KCNN3 and KCNMA1) and one belongs to the voltage 
gated k+ channel family (KCNQ5). Recently, the KCNQ family of k+ channels have been 
described to have a determinant role in chemoreceptor function in RTN (Mulkey et al., 
2015); moreover, it was reported that the overexpression of KCNN3 channel cause cardiac 
and respiratory problems (Mahida et al., 2014), suggesting that they are potential 
therapeutic targets for the treatment of respiratory dysfunction. 
qRT-PCR analyses (Fig.22) showed that PHOX2B depletion strongly increased by 2-fold KCNQ5 
mRNA level in KO clone compared to native IMR32 and scramble transfected cells (Fig.22A, 
black bar vs white and grey bars). KCNN3 mRNA expression was also significantly increased, 
although to a lesser degree (Fig.22B, black bars vs white and grey bars). No difference in the 
KCNMA1 mRNA expression level was reported between PHOX2B knockout cells and control 
cells (Fig.22C, black bar vs white and grey bars).    
Collectively, these data confirm the previous observation that potassium channels are PHOX2B 
target genes and moreover, surprisingly, they suggest that PHOX2B modulates negatively the 
expression of these genes.  
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Fig.22 Potassium channels expression. qPCR analysis of endogenous KCNQ5 (A), KCNN3 (B) and KCNMA1 (C) mRNA 
expression normalised to that of the GAPDH gene in native IMR32 (white bar), PHOX2B K.O clone A6.4 (black bar) and 
SCR (grey bar). The bars indicate the relative fold induction in PHOX2B K.O clone A6.4 and SCR with respect to the 
native IMR32 (=1) calculated using the 2-ΔΔCt method and are expressed as the mean values ± SD (error bars) of at least 
three independent experiments, performed in triplicate. A: *p < 0.05, statistically significant differences in KCNQ5 
mRNA levels between K.O clone and IMR32 and SCR, respectively (one-way ANOVA, Tukey’s test). B: **p < 0.01 and 
*p< 0.05, statistically significant differences in KCNN3 mRNA levels between K.O clone and IMR32 and SCR, 
respectively (one-way ANOVA, Tukey’s test). 
 
 
We then investigated the role of PHOX2B on sodium channels expression. A significant up-
regulation of SCN2A and SCN3A mRNA by 2- and 3-fold, respectively, was observed in clone 
A6.4 compared to IMR32 and scramble transfected cells (Fig.23A and B, black bar vs white 
and grey bars). SCN8A channels encoding gene expression also increased in the absence of 
PHOX2B but to a lesser degree (Fig.23C black bars vs white and grey bars). In contrast to 
SCN2A, SCN3A and SCN8A, we observed a not specific decrease in SCN9A mRNA levels, as its 
level detected in the A6.4 clone parallels that in the scramble transfected cells (Fig.23D, black 
and grey bars vs white bar). 
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Fig.23 Sodium channels expression. qPCR analysis of endogenous SCN2A (A), SCN3A (B), SCN8A (C) and SCN9A (D) 
mRNA expression normalised to that of the GAPDH gene in native IMR32 (white bar), PHOX2B K.O clone A6.4 (black 
bar) and SCR (grey bar). The bars indicate the relative fold induction in PHOX2B K.O clone A6.4 and SCR with respect to 
the native IMR32 cells (=1) calculated using the 2-ΔΔCt method and are expressed as the mean values ± SD (error bars) 
of at least two independent experiments, performed in triplicate. A and B: * p < 0.05, statistically significant 
differences in SCN2A and SCN3A mRNA levels between K.O clone and IMR32 and SCR, respectively (one-way ANOVA, 
Tukey’s test).  
 
 
These data demonstrated that also sodium channels are PHOX2B target genes and confirmed that 
PHOX2B, usually considered as a positive regulator of transcription is also able to negative regulate 
the expression of ion channels. So far, only two genes have been identified that are negatively 
regulated by PHOX2B: MSX-1 (Revet et al., 2008) and SOX10 (Nagashimada et al., 2012), 
important for the correct development of the ANS. The reciprocal negative regulation 
between Phox2b and Sox10 plays a crucial role in generating appropriate numbers of neurons 
and ganglia in the ANS (Fig.3). Processes of vital importance for the neuron, such as its 
differentiation or electrical activity must be finely regulated. Therefore, we can hypothesize 
that PHOX2B could play a repressive role on transcription of its target genes that have to be 
fine-tuned for a correct function of the neuron.  
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The main potential pitfall with the CRISPR-Cas9 system is the risk of cross-reactivity of gRNA with 
target sites in different genes that shear a similar sequence. To rule out the possibility that 
the increase in KCNN3 and KCNQ5 mRNA levels observed in PHOX2B knockout cells was due 
to an off-target effect, we performed a “rescue” experiment with the expression of WT 
PHOX2B protein.  
Expression of WT PHOX2B protein in clone A6.4 knockout cells (Fig.24 black bar) was not however 
capable of inducing any change in the KCNN3 and KCNQ5 mRNA expression levels with 
respect to mock-transfected cell (Fig.24A and B, black bars vs white bars). As control A6.4 
clone has been transfected with empty vector (Fig.24A and B, black bars vs grey bars). 
 
 
 
 
Fig.24 Expression of PHOX2B does not rescue potassium channels expression in PHOX2B K.O cells. qPCR analysis of 
endogenous KCNN3 (A), KCNQ5 (B) and KCNMA1 (C) mRNA expression normalised to that of the GAPDH gene in clone 
A6.4 (white bar) transfected with PHOX2B WT V5/HIS (black bar) and with empty vector V5/His as control (grey bar). 
The bars indicate the relative fold induction in cells transfected in relation to the not transfected cells (MOCK =1) 
calculated using the 2-ΔΔCt method and are expressed as the mean values ± SD (error bars) of at least two independent 
experiments, performed in triplicate.  
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Although these results may suggest that the effects so far described are not due to PHOX2B 
depletion, but otherwise to an off-target effect, we cannot rule out that the missed down-
regulation, as we expected, of ion channels by WT PHOX2B was due to a not sufficient 
expression of the WT protein in these cells. It is well known that neuroblastoma cell lines are 
difficult-to-transfect cells. 
In order to avoid this problem, we tested different transfection parameters, by changing the DNA 
plasmid construct (PHOX2B WT V5/His and PHOX2B WT Mic/His encoding plasmids) and the 
transfection reagent (Fugene HD vs LIPOFECTAMINE 3000). Figure 25 shows the 
quantification of PHOX2B mRNA expression after PHOX2B construct transfection in clone 
A6.4, which results in a highly variable transfection efficiency in different experiments. 
However, cells expressed very low level of PHOX2B and no significant alteration was observed 
in the expression of potassium channels, even in the experiment with the higher level (3-fold) 
of PHOX2B expression (Fig.25 red triangle) (data not shown).  
 
 
Fig.25 mRNA expression level of transfected PHOX2B WT in clone A6.4 with two different transfection reagents. 
Symbols indicate the mRNA levels of transfected PHOX2B knockout cell with two different constructs encoding for 
PHOX2B WT with two transfection reagents in order to optimize transfection efficiency. The level of mRNA is 
expressed as relative expression normalised to that of the GAPDH gene and expressed according the 2-ΔCt method. 
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Given that PHOX2B knockout cell clone still expresses endonuclease Cas9 that can recognize the 
PAM sequence presents in the PHOX2B WT transfected DNA, we considered the hypothesis 
that the low expression of PHOX2B in transfected cells was due to the cleavage activity of this 
enzyme. To test this hypothesis, we transfected A6.4 cells with two constructs encoding for 
PHOX2B +7 and +13 Alanine mutant protein to study also the effect of mutant protein in the 
expression of ion channels genes. The empty vector V5/HIS was used as control. 
Unexpectedly, the expression of +7 and +13 Alanine mutant proteins significantly increase 
KCNN3 mRNA expression in A6.4 cells compared to control (Fig.26A hatched bars vs white 
bars), whereas no significant changes were observed in KCNQ5 and KCNMA1 channel mRNA 
levels (Fig.25B and C).  
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Fig.26 Mutant proteins up-regulate KCNN3 channel expression. qPCR analysis of endogenous KCNN3 (A), KCNQ5 (B) 
and KCNMA1 (C) mRNA expression normalised to that of the GAPDH gene in clone A6.4 (white bar) transfected with 
PHOX2B +7 and +13 V5/HIS (black hatched bar) and with empty vector V5/HIS as control (grey bar). The bars indicate 
the relative fold induction in cells transfected with respect to the mock-transfected cells (=1) calculated using the 2-ΔΔCt 
method and they are expressed as the mean values ± SD (error bars) of at least two independent experiments, 
performed in triplicate. A: **p < 0.01 and *p < 0.05, significant differences in KCNN3 mRNA level between cl. A6.4 cells 
transfected with PHOX2B +7 vector and cells not transfected or transfected with empty vector, respectively. ### p < 
0.001 and ## p < 0.01, significant differences in KCNN3 mRNA level between cl. A6.4 cells transfected with PHOX2B +13 
vector and cells not transfected or transfected with empty vector, respectively (one-way ANOVA, Tukey’s test). 
 
 
 
 
 
The expression of the mutant proteins does not seem to be affected by the presence of 
endonuclease Cas9, so we excluded the possibility that this mechanism could be responsible 
for the low expression of PHOX2B WT protein. PHOX2B KO cells appeared to be not prone to 
PHOX2B overexpression. Furthermore, the effect of PHOX2B mutation on the expression of 
KCNN3 was only detectable when cells have been efficiently transfected (at least 10 times 
over basal PHOX2B mRNA level; data not shown) confirming the difficulty in modulating 
PHOX2B levels in this cellular system. However, this aspect deserves further investigation. 
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In conclusion, the data obtained in clone A6.4 confirmed that  
- ion channels encoding genes are indeed PHOX2B target genes 
- PHOX2B negatively modulates the expression of KCNN3, KCNQ5 potassium channels genes 
and SCN2A, SCN3A, SCN8A Na+ channels genes. 
- The over expression of +7 and +13 Alanine mutant proteins exacerbates the up-regulation 
of KCNN3, thus confirming that PHOX2B mutant proteins affect the expression of its target 
genes in a gene-dependent manner 
- PHOX2B mutant proteins have acquired a gain of function activity in the expression of 
KCNN3 gene. 
 
 
Study of the role of the PHOX2B mutant protein on the expression of ion 
channels in the native IMR32 cell line 
 
CCHS is due to heterozygous mutations of PHOX2B. The gain of function acquired by the mutant 
proteins in the expression of the KCNN3 gene has been detected in a system depleted of WT 
PHOX2B. In order to confirm that PHOX2B mutant proteins lead to a de-regulation of KCNN3 
expression also in the presence of WT PHOX2B protein, we studied how the mutant protein 
(+7 Alanine) affects the expression of ion channel genes in native IMR32 cell line. As with the 
A6.4 clone, IMR32 native cells were difficult to transfect with the WT PHOX2B protein  
Analysis of mRNA (Fig.27) extracted from IMR32 cells with higher level of expression of 
transfected WT PHOX2B did not reveal any significant alteration in the expression of 
potassium channel genes compared to mock-transfected sample and cells transfected with 
empty vector (Fig.27 horizontal hatched bars VS white and grey bars). On the contrary, the 
overexpression of mutant protein bearing the +7 Alanine mutation increased KCCN3 mRNA 
expression (Fig.27 A vertical hatched bar VS white and grey bars) confirming the results 
obtained in clone A6.4. Likely to clone A6.4, KCNQ5 and KCNMA1 channels gene expression 
(Fig.27 B and C) was not affected, as no differences were measured between transfected and 
not transfected sample. 
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Fig.27 Mutant protein effect on ion channels genes expression in IMR32 cells. qPCR analysis of endogenous KCNN3 
(A), KCNQ5 (B) and KCNMA1 (C) mRNA expression normalised to that of the GAPDH gene in native IMR32 (white bar) 
transfected with PHOX2B WT and +7 V5/HIS (black hatched bar) and with empty vector V5/HIS as control (grey bar). 
The bars indicate the relative fold induction in cells transfected with respect to the not transfected cells (MOCK =1) 
calculated using the 2-ΔΔCt method and expressed as the mean values ± SD (error bars) of at least one experiment, 
performed in triplicate.  
 
 
 
 
 
We recently published that PHOX2A can interact with mutated version of PHOX2B (Di Lascio et al. 
2016), rescuing the impaired transcriptional activity of mutant proteins. Although additional 
study will be needed to further evaluate the significance of this finding, we can speculate that 
the effect of mutant proteins on the expression of ion channels genes might be mediated by 
the interaction between the two proteins. Furthermore, we showed that potassium channels 
genes are co-regulated by PHOX2B and PHOX2A, and that PHOX2A is up-regulated in PHOX2B 
A6.4 K.O cells. All together these findings led us to hypothesize that PHOX2A may play a role 
in the up-regulation of ion channels genes. We therefore investigated the effect of PHOX2A 
on ion channel expression in IMR32 cell line transiently transfected with PHOX2A expression 
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vector (Benfante et al., 2007) and with an empty vector (pCMV-myc) as control. PHOX2A 
overexpression affects the expression of four ion channels: KCNQ5 and SCN9A expression 
level is significantly reduced, whereas SCN3A and KCCN3 genes are significantly up-regulated, 
with respect to cells transfected with the empty vector (Fig.28). In particular, KCNN3 
expression level is 1.6-fold significantly higher than in control cells (FIG.26 white bar). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.28 PHOX2A over-expression affects ion channels genes expression. qPCR analysis of endogenous ion channels 
mRNA expression normalised to that of the GAPDH gene in native IMR32 transfected with PHOX2A expressing vector 
and with empty vector pCMV-myc as control (white bar). The bars indicate the relative fold induction in cells 
transfected in relation to cells transfected with the empty vector (CMV=1) calculated using the 2-ΔΔCt method and are 
expressed as the mean values ± SD (error bars) of at least three experiments, performed in triplicate. ***p < 0.001, 
**p < 0.01 and *p < 0.05, significant differences in KCNN3, KCNQ5, SCN3A and SCN9A mRNA levels between IMR32 
cells transfected with PHOX2A expressing vector and control (one-way ANOVA, Tukey’s test). 
 
 
 
In conclusion, our data demonstrate that some of the ion channels we investigated are PHOX2B 
target genes, which negatively modulates their expression. In particular, we showed that the 
KCNN3 channel gene expression is highly affected by the presence of mutant proteins (both in 
native IMR32 cell line and in PHOX2B K.O cells) and by the up-regulation of PHOX2A in native 
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cells, suggesting that it is a potential therapeutic target for the treatment of respiratory 
dysfunction. Further investigations are however mandatory in order to answer the following 
questions: 
- Are the different expression levels of ion channel genes in clones A6.4 due to the absence 
of PHOX2B and not to morphological differentiation-associated changes? 
- Is the effect of the mutant proteins on the expression of KCNN3 due to the formation of 
hetero-dimer between PHOX2A and PHOX2B mutant protein? 
To answer these questions the same experiments will be repeated in the other PHOX2B depleted 
clones and in IMR32 cells transiently silenced for PHOX2B. Furthermore, silencing of PHOX2A 
in the A6.4 clone may give some insights in the mechanism leading to the up-regulated 
expression of KCNN3 by the mutant proteins. 
 
Electrophysiology study on PHOX2B knockout cells 
 
Ion channels and in particular, potassium channels are the primary determinants of neuronal cell 
excitability and several findings suggest that are involved in neuronal development and the 
modulation of respiratory activity in vivo (Bond at al., 2000; Torrecilla et al., 2013; Mulkey et 
al., 2015). 
We identified ion channels as PHOX2B target genes and showed that the presence of mutations in 
PHOX2B may lead to the de-regulation of their expression. Due to the role of the K+ and Na+ 
ions in the action potential generation and in the restoring of the resting membrane 
potential, we asked whether deregulated ion channels expression might impair the 
electrophysiological properties of neuronal cells. In collaboration with Dr. Flavia Antonucci 
(University of Milan) we measured total ion currents induced by injection of hyper-to-
depolarizing currents in PHOX2B knockout cells (clone A6.4) and IMR32 native cells. 
Whole-cell current clamp experimental paradigm was used, and repeated pulses of current 
starting from the resting membrane potential of the cell were injected. Preliminary data 
showed important differences between the two cell types when a series of hyperpolarizing 
currents ranging from 120 pA to 240 pA (20 pA/step, 30 sweep) were injected (Fig.29). 
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Indeed, the degree of hyperpolarization, in the presence of comparable current injection, 
appears larger in clone with respect to the control (point 1-green), thus suggesting 
unbalanced expression of Na+ and K+ channels at the membrane.  Accordingly, the occurrence 
of a more prominent voltage sag (point 2-light blue) in CRISPR cells suggest an altered 
presence of hyperpolarization-activated cation channels (I h), which are a subset of voltage-
gated channels permeable to both Na+ and K+ ions known to be crucial for the determination 
of intrinsic excitability. Moreover, after hyperpolarizing current pulse only rebound 
depolarization can be found in PHOX2B KO cells in contrast to the action potential recorded in 
normal cultures (point 3-red) indicating that the membrane potential of A6.4 clone cells is 
more hyperpolarized than control cells thus limiting their response stimulation. 
 
Fig.29 Total ion current in IMR32 cells and PHOX2B K.O cells. Whole-cell current clamp was used to determine 
electrophysiological properties of IMR32 and CRISPR cells by repeatedly injecting pulse of current starting from the 
resting membrane potential of the cell. PHOX2B K.O cells reported only rebounded depolarization (point red), higher 
voltage drop (green arrow) and higher voltage sag (blue arrow) in comparison with IMR32 cells 
 
 
 
 
Although additional study will be needed to further evaluate the significance of this 
electrophysiological changes, we can speculate that changing in ion channels mRNA 
expression induce aberrant electrophysiological property. It will be interesting to study how 
the mutated protein alters the electrical properties of the cell and by using selective blockers 
for sodium and potassium currents we will be able to understand which of the two currents 
are most dysregulated. 
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Discussion 
 
CCHS is a rare neonatal lifelong and life-threatening disorder. It is characterized by hypoventilation 
and ANS dysregulation. The hallmark of CCHS is reduced or short and shallow breathing due 
to dysregulation of the respiratory drive especially evident during NREM sleep. The inability of 
CCHS patients to control breathing results in the need for life-long ventilatory support during 
sleep; in the most severe cases, also in the daytime.  
In 2003 PHOX2B gene was identified as the disease-causing gene; PHOX2B gene encodes for a 
transcriptional factor required for the development of neurons that regulate the 
cardiovascular, respiratory and digestive organs, forming the sensory and motor arms of 
visceral reflex circuits (Amiel et al., 2003). 
The laboratory, in which I carried out the doctoral thesis, has been studying for years the 
transcription factor PHOX2B, with particular attention to the molecular mechanisms that link 
the mutations of this gene to the pathogenesis of CCHS with the perspective to identify a 
possible pharmacological treatment. Indeed, up today, there is no cure for CCHS. 
The aim of this thesis was to identify potential pharmacological targets for the development of 
molecules that can be chronically administered to CCHS patients in order to improve their 
respiratory symptoms and the quality of life. We have addressed this problem with two 
different experimental approaches:  
• starting from a clinical report (Straus et al., 2010) we investigated the molecular 
mechanisms underlying the recovery of chemosensitivity, observed in two CCHS patients, 
following the administration of the progestinic desogestrel, to identify potential 
pharmacological targets for the development of alternative molecules lacking 
contraceptive activity that can be administered to both female and male patients; 
• Using a genome-wide approach, (ChIP-seq) we identified 3000 candidate PHOX2B target 
genes. We discovered that the expression of some of them is dysregulated when PHOX2B 
is mutated and they could be responsible for the clinical symptoms of the disease. These 
findings open up the possibility that these new PHOX2B target genes could be new 
pharmacological targets in the perspective of rescuing their normal activity. 
I discuss these two parts of my thesis in separate sections. 
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The progestinic desogestrel down-regulates PHOX2B: new therapeutic 
strategy in CCHS 
 
In 2010, a new pharmacological perspective emerged from the observation of two clinical cases of 
particular interest. Straus and collaborators published a work in which they reported of two 
female CCHS patients, of different ages, carrying different poly-alanine expansions in the 
PHOX2B gene (+6 and +5, respectively), which showed a marked recovery of the hypercapnia 
response following chronic progestogen intake desogestrel, for contraceptive purposes.  
The interest in the possibility of a pharmacological intervention able to improve the clinical 
condition of CCHS patients has increased especially after the emerging evidence that sites, 
responsible of central chemoreception in central nervous system, may be partially preserved 
in CCHS patients. This observation, in accordance with the known ability of the progestins to 
stimulate the ventilation (Boukari et al., 2017; Shahar et al., 2003), has led to the hypothesis 
that there was a link between the intake of the progestin and the recovery of chemo 
sensitivity in these patients (Straus et al. 2010).  
Recent experiments conducted in adult mice claimed that several neurones (such as those located 
in medullary and supramedullary areas of the CNS) are involved in the effect mediated by 
desogestrel (Joubert et al., 2016; Loiseau et al., 2014).  
Our initial working hypothesis was that the progestin desogestrel could act directly on the 
transcription factor PHOX2B influencing its expression and consequently the expression of its 
target genes. The effect of desogestrel on the expression of PHOX2B was tested in vitro in the 
human neuroblastoma SK-N-BE(2)C cell line. As described in our published work “Desogestrel 
down-regulates PHOX2B and its target genes in progesterone responsive neuroblastoma 
cells” (Cardani et al., 2018), we demonstrated the existence of a direct link between the 
progestin desogestrel and PHOX2B, as 3-KDG, active metabolite of the desogestrel, reduces 
the expression of PHOX2B and its target genes, by means of a post-transcriptional 
mechanism. Moreover, 3-KDG treatment was also able to reduce the level of PHOX2B +7 
Alanine expanded protein, that is one of the most common mutations found in CCHS patients. 
The polyalanine expanded PHOX2B proteins show a reduced ability to transactivate both its own 
promoter and that of target genes, in a promoter-specific manner (Di Lascio et al., 2013). The 
 83 
 
length of the expanded stretch is inversely proportional to the function of the protein. 
Furthermore, mutant proteins reduce the activity of WT protein, by a dominant-negative 
mechanism, and moreover, they acquire a toxic function with the formation of both nuclear 
and cytoplasmic aggregates, that partially sequester the normal protein, limiting its 
physiological activity (Di Zanni et al., 2012). Other mechanisms involving squelching of co-
factors, PHOX2B decreased binding affinity for its consensus sequences, or defect in protein 
folding have been hypothesized (Di Lascio et al., 2013; Trochet et al., 2005; Bachetti et al., 
2005; Durand et al., 2005; Goridis et al., 2010; Dubreuil et al., 2008). These data led to 
investigate the pathway linked to aggregates removal and /or protein refolding as possible 
druggable targets) (Bachetti et al., 2007; Parodi et al., 2012). 
Since CCHS is a pathology that occurs in heterozygosis, the search for a therapy can follow two 
major approaches: by developing drugs that can reduce the pathological effect of the 
mutated forms of PHOX2B or by identifying molecules capable of significantly enhancing the 
physiological activity of the WT protein in order to compensate the toxic effect of mutated 
forms. So far, most of the published studies aimed to the identification of molecules able to 
rescue the activity of the mutant protein or to eliminate it, without considering the effects 
that these treatments have on the WT protein (Di Zanni et al., 2012; Parodi et al., 2012; 
Bachetti et al., 2007).  
Our data support the hypothesis that beneficial treatment of breathing defects has to go through 
the reduction of the mutant protein, although this will affect also the WT protein. The exact 
role of PHOX2B in adults has not been clarified yet; however, it has been shown to be 
important for maintaining the functionality of noradrenergic neurons and control orofacial 
movement, auditory and eyes function (Fan et al., 2011; Kang et al., 2007). 
We are aware that the SK-N-BE(2)C cell model used in this study has important limitations as it 
does not properly represent the human pathophysiology. The difference in the kinetics of 
PHOX2B reduction in the two SK-N-BE(2)C over-expressing hPGR clones may be due to the 
different levels of expression of PGR-B compared to PGR-A isoform. The exact contribution of 
the two isoforms of progesterone receptor, PGR-B and PGR-A, in mediating the mechanism of 
action of the 3-KDG is still unknown and further investigation will be needed to better 
understand it. Moreover, we do not expect that in vivo the progestin desogestrel reduces the 
expression of PHOX2B in such a drastic manner; we can hypothesize that in CCHS patients the 
 84 
 
reduction of  WT and mutant PHOX2B protein is mild but could be sufficient to counteract the 
toxic effects of the mutant protein contributing to the recovered chemosensitivity and 
increased ventilation observed in the two CCHS patients, without impairing totally the 
function of the WT protein. The effect of desogestrel on PHOX2B target genes corroborate 
the importance of this finding as we can hypothesize that other genes, whose expression is 
deregulated because of the toxic effect of the mutant protein, may now be expressed at level 
compatible with a quasi-normal activity of neurons affected by PHOX2B mutations, in 
particular in those patients carrying mutant PHOX2B with milder phenotype (+5 to +7 
Alanine). 
This is in agreement with the two patients reported in the clinical study by Straus and colleagues 
carrying PHOX2B +5 and +6 Alanine mutations, that showed a mild phenotype. Recently the 
same authors reported of another patient not responding to desogestrel (Loiseau et al. 2017). 
Therefore, we can speculate that any possible difference in clinical response to 
pharmacological treatment might be related to the presence of different mutations. In the 
presence of mutant proteins with shorter expansion (e.g +5 and +6 Alanine) the damages, at 
the level of PHOX2B+ neurons, could be less serious than the damages that occurred in the 
presence of mutant proteins with longer expansion (e.g. +13 Alanine). In this last case, the 
reduction of the protein level could be not sufficient to restore, at least partially, the function 
of those neuronal structures affected by mutation and involved in breathing control. 
We can speculate that the clinical observation made by Straus and co. is given by a general effect 
of desogestrel that can act through both PHOX2B+ and PHOX2B- expressing neuronal circuits. 
Our data, by showing for the first time the presence of a direct link between desogestrel and 
PHOX2B, have a proof of concept value that, although CCHS is a neurodevelopmental 
disorder, by modifying the activity of PHOX2B and its mutant counterparts, it is possible to 
conceive new pharmacological interventions with benefits for CCHS patients and their 
families and thus leading to a better quality of life. Studies have been conducted with the aim 
to find out molecules capable of reducing PHOX2B expression in neuroblastoma cell lines (Di 
Zanni et al., 2015). 
In this contest, the identification of new and sensitive intracellular therapeutic targets has to take 
into an account the role of PHOX2B target genes, whose de-regulation may explain the 
molecular pathogenic mechanisms underlying CCHS, but they can also represent druggable 
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targets to by-pass PHOX2B mutations. 
 
Ion channels are PHOX2B target genes: new possible pharmacological 
targets 
 
The hallmark of CCHS is the presence of hypoventilation. However, as PHOX2B is important for the 
development of the ANS, CCHS patients present a more generalized autonomic dysfunction 
(reviewed in Weese-Mayer, 2017). The cardiovascular system is affected; CCHS patients with 
PARM mutation reported also cardiac asystoles and some of them need cardiac pacemaker 
implantation, even at a young age. In addition, other cardiovascular symptoms can include 
altered temperature regulation, altered blood pressure regulation, altered heart rate 
variability and poor circulation. Gastrointestinal manifestations are common. The symptoms 
are present in both PARM and NPARM CCHS patients and can vary from a mild reflux and 
poor upper gastrointestinal motility to a more severe HSCR that need surgical treatment. In 
some cases, CCHS patients present ophthalmological problems like strabismus, abnormal 
pupil dilation, Marcus Gunn jaw-winking syndrome and absent or reduced depth perception. 
PHOX2B mutations can also affect the endocrine system with growth hormone deficiency and 
congenital hyperinsulinemia. Other patients are affected by neurological disorders such as 
neurocognitive impairment and poor school performance, epilepsy episodes and moreover, 
they can develop tumours of neural crest origin, such as ganglioneuromas, 
ganglioneuroblastomas, and NB.  
We hypothesized that CCHS is the results of the abnormal expression of PHOX2B target genes due 
to the presence of PHOX2B mutation that lead a general transcription dysregulation. This 
transcriptional defect could be due to a reduction or lack of expression of target genes 
positively regulated, or to an increase in the expression of those genes negatively regulated 
by PHOX2B. Besides the difference in the behaviour and function of different PHOX2B mutant 
proteins, the severity of the disease could be linked to the importance and number of 
dysregulated target genes, as we have demonstrated that different mutations affect the 
expression of target genes in a promoter-specific manner (Di Lascio et al., 2013). In this 
perspective, the identification of the PHOX2B target genes is crucial for a future therapeutic 
intervention in CCHS, capable of restoring the correct level of expression of these targets by-
 86 
 
passing PHOX2B mutations. 
ChIP using anti-PHOX2B antibodies, previously generated and characterized in our laboratory, 
followed by a genome wide sequence, has allowed us to identify more than 3000 genes, 
possible candidate PHOX2B target genes. Recently, two independent groups published the 
results of ChIP-seq analyses carried out with PHOX2B antibodies in different neuroblastoma 
cell lines (Boeva et al., 2017; Durbin et al., 2018). The results match with and reinforced our 
findings.  
Very interesting, among the newly identify PHOX2B target genes, we found genes encoding ion 
channels, including those selective for potassium and sodium channels. Potassium channels 
are a huge and ubiquitous family of membrane proteins that play important roles in vital 
cellular signalling processes and are expressed in both excitable and non-excitable cells. They 
are involved in processes that regulate neurotransmitter release, heart rate, insulin secretion, 
neuronal excitability, epithelial electrolyte transport, smooth muscle contraction. Moreover, 
it has been reported their involvement in the maintenance of respiratory rhythm and central 
chemosensitivity in isolated brainstem-spinal cord preparations of rat neonates (Okada et al., 
2005). Mutations in K+ channels and or altered regulation of their function are associated with 
various disorders, such as diseases of the heart, kidney, pancreas, and CNS. On the other 
hand, Na+ channels are responsible for the generation and propagation of action potentials 
and they have been shown to play a central role in the genesis of epilepsy. 
Since CCHS patients presented respiratory problem, cardiac alteration and epilepsy and, both 
potassium and sodium channels are involved in these symptoms, we investigated whether 
and how they could be de-regulated in CCHS. An altered expression could be responsible and 
explain an important part of the symptoms manifested by CCHS patients. In particular, 
KCNN3, KCNQ5, KCNMA1 and SCN2A, 3A, 8A and 9A channels are of particular interest since 
they have been demonstrated to be involved in respiratory and cardiac problem and in the 
onset of epileptic episodes (Mulkey et al., 2015; Mahida et al., 2014; Catterall 2012). 
To demonstrate that the genes, identified for the property of their genome sequences to be 
bound by PHOX2B, were also regulated by PHOX2B, we took the advantage of an IMR32 cell 
clone (A6.4) in which we knocked-out PHOX2B gene expression by CRISPR/Cas9 editing 
technology. It is really interesting underlying that this clone expresses the PHOX2B transcript 
at normal level, whereas the protein is completely absent. Usually mRNAs encoding 
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premature termination variants, like clone A6.4, are degraded by nonsense-mediated RNA 
decay (NMD) mechanism. NMD is a post-transcriptional quality control that targets mRNAs 
harbouring a premature termination codon to the degradation pathway thus preventing the 
formation of truncated protein with potentially toxic effect (Juffrey and Wilkinson 2018). 
Moreover, this mechanism regulates a substantial number of protein-coding transcripts 
directly and indirectly and recently it has been reported as an important modulator of neural 
development and disease (Mendell et al., 2004; Juffrey and Wilkinson 2018). We can 
hypothesise that the PHOX2B mRNA is able to escape degradation by the NMD pathway.  
Indeed, there are no reports indicating that PHOX2B mRNA is targeted by NMD; moreover, it 
has been already demonstrated that mRNAs encoding PHOX2B bearing nonsense mutations 
are capable of escaping NMD thus supporting our hypothesis (Cain et al., 2017; Trochet et al., 
2009). On the other hand, we have recently demonstrated that the kinetics of PHOX2B mRNA 
degradation is biphasic (Cardani et al., 2018), similar to the process described for those 
mRNAs regulated by NMD (Trcek et al., 2013) thus suggesting that only a portion of PHOX2B 
mRNA may be degraded by NMD. This aspect deserves further investigation. 
Clone A6.4, although missing PHOX2B expression, still maintains the features of noradrenergic 
neurons, but with the characteristics of a more mature stage of neuronal differentiation. This 
has been demonstrated by the increased expression in the neuronal marker β3 tubulin and 
the vesicular secretory markers synaptotagmin and syntaxin, by the lack of expression of 
SOX10, a marker of the glial lineage, and by the reduction in ChAT protein expression. This is a 
marker of the cholinergic lineage that can be co-expressed during development of the 
sympatho-adrenal neurons until the colinergic-cathecolaminergic switch has been completed. 
This data is also confirmed by the increase in PHOX2A expression level compared to native 
IMR32 cells and the maintenance of DBH. The up-regulation of PHOX2A was unexpected since 
PHOX2A is positively regulated by PHOX2B. Both DBH and TLX2 are PHOX2B and PHOX2A 
target genes and their expression was not affected by the absence of PHOX2B protein. 
Murine models in which the two genes were alternatively expressed in the each other locus, 
demonstrated that Phox2b and Phox2a genes are not functionally equivalent and Phox2a is 
not able to compensate for the absence of Phox2b (Coppola et al., 2005). However, from our 
data we can suppose that in the A6.4 clone the overexpression of PHOX2A is due to a 
compensatory mechanism, leading to the maintenance of DBH and TLX2 expression level. Our 
data are in line with those recently published by Boeva et al. (2017), showing that the 
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silencing of PHOX2B does not affect the expression of catecholaminergic marker such as DBH 
(Boeva et al., 2017). 
The observed changings suggest that clone A6.4 recapitulates the differentiation process observed 
during development. It has been demonstrated that the reduction of expression of PHOX2B is 
necessary in a specific time window to allow the exit from the cell cycle of the neuronal 
precursors, and their terminally differentiation to sympathetic neurons (Paris et al., 2006; 
Dubreuil et al., 2000). Thus, we cannot exclude that any variation observed in the expression 
levels of the putative target genes is due to the lack of PHOX2B alone or to the differentiation 
process. However, due to the maintenance of its general noradrenergic phenotype, the A6.4 
clone still represents a good model for an initial validation screening of the newly identified 
PHOX2B target genes. 
Using PHOX2B KO stable clone A6.4, we found that PHOX2B negatively modulates the expression 
of K+ and Na+ channels, as, in the absence of PHOX2B protein expression, the mRNA level of 
KCNN3, KCNQ5 and SCN2A is increased. Moreover, re-expression of PHOX2B mutant protein 
bearing +7 and +13 Alanine expansion has demonstrated, for the first time, that PARM 
mutations can confer new enhanced PHOX2B mutant protein activity on the transcriptional 
regulation of KCNN3 channel, as its expression is further increased in the presence of the 
mutant proteins. In addition, when tested in a cellular model expressing PHOX2B WT protein, 
the gain of function activity acquired by the mutant protein has a dominant-negative effect 
on the transcriptional activity of the wild-type protein, thus maintaining the expression of 
KCNN3 higher compared to not transfected cells. 
We recently published (Di Lascio et al., 2016) that the dominant-negative effect of mutant 
proteins on PHOX2B WT activity is not due to direct interaction of the mutant proteins with 
their WT counterpart, but other mechanisms involving squelching of co-activators or aberrant 
interactions with other regulatory proteins can be supposed. PHOX2A heterodimerizes with 
PHOX2B and several genes are co-regulated by the two proteins. Our findings (Di Lascio et al., 
2016) demonstrated that PHOX2A is capable of interacting with PHOX2B mutant proteins, 
thus rescuing their impaired transcriptional activity. Moreover, preliminary data show that 
the overexpression of PHOX2A in neuroblastoma IMR32 cell line induces the expression of 
KCNN3. These results support the idea that PHOX2A may be involved in the up-regulation of 
KCNN3 expression by the PHOX2B mutant proteins, a mechanism that deserves further 
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investigation.  
The increased expression of ion channels is associated with an altered electrical activity of the cell 
clone. Data from the literature (Mulkey et al., 2015; Mahida et al., 2014; Catterall 2012) 
support the hypothesis that CCHS may be due to de-regulation of ion channels expression 
and/or activity, a mechanism that could explain some respiratory and non-respiratory 
symptoms. The basic rhythm of breathing is generated within the pre-BötC and the 
RTN/pFRG. This brainstem respiratory network receives information about the arterial levels 
of pO2, pCO2/pH, and pH from chemoreceptors and adjusts respiratory motor output, 
ensuring appropriate ventilation of the lungs in various conditions. In mammals, respiratory 
inputs originate primarily from the receptors in the CB and from the central chemoreceptors 
in the brainstem especially from neurons of RTN and bulbar serotonergic neurons of the 
raphe nuclei (Guyenet et al., 2008; Corcoran et al., 2009). These two structures are critically 
important for maintaining breathing and it has been demonstrated that some of the ion 
channels regulated by PHOX2B are expressed in populations of neurons in these structures. 
 Recent evidence showed that some voltage gated K+ channel of the KCNQ family are expressed in 
the RTN and they had key roles in the determination of RTN chemoreceptor function (Mulkey 
et al., 2015). The authors reported that they are essential determinants of spontaneous 
activity in RTN, and downstream effectors for serotonergic modulation of breathing, in a 
murine model. Moreover, loss of function mutations in KCNQ channels can cause epilepsy.  
The small-conductance Ca2+-activated potassium channel, KCNN3 or SK3, is responsible for the 
slow after-hyperpolarization that usually follows an action potential. This protein is widely 
expressed in the murine brain (Bond et al., 2000), including hippocampal formation, striatum, 
in subsets of neocortical neurons, thalamus, cerebellum, brain stem and, very interesting, in 
neuronal populations of the medulla oblongata, which are involved in the processing of 
respiratory signals. SK3 is also express in skeletal muscle and in cardiomyocytes. Recently it 
has been demonstrated that overexpression of the SK3 channel is associated with high 
incidence of sudden death and increases susceptibility to cardiac arrhythmic syndromes, 
including heart block and bradyarrhythmias, slowed ventricular conduction, and respiratory 
problems (Mahida et al., 2014). 
Voltage-gated Na+ channels (SCN1A, 2A, 3A and 8A) are the primary sodium channels in the CNS. 
In mice, NaV1.2 channel is primary localized in unmyelinated or pre-myelinated axons and 
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dendrites and participates in the generation of both axonal and somatodendritic action 
potential. It is well established that mutations that cause alteration in sodium channels 
activity are responsible for genetic epilepsy syndromes with a wide range of severity (Catterall 
2012). 
All these finding support our hypothesis that transcriptional dysregulation and dysfunctions of K+ 
and Na+ channels activity may contribute to the onset of respiratory and cardiac problems 
and epilepsy episodes associated with CCHS and suggest that these proteins are promising 
potential target for a therapeutic intervention in CCHS. Due to the important role that these 
ion channels have on neuronal physiology, restoring their expression and/ or activity to the 
normal physiological level can by-pass PHOX2B mutant effects, leading to amelioration of 
CCHS symptoms. Moreover, several drugs targeting these proteins are already used in clinics, 
thus prompting the idea that the potential progress toward a therapeutic intervention to 
treat CCHS is today more than concrete. 
 
Limitation  
 
The results presented in this thesis are subject to a number of limitations. 
The validation of PHOX2B target genes was performed only in one stable clone. Due to observed 
progression of the clonal cells towards a more differentiated phenotype, the obtained data 
will be confirmed in the other PHOX2B knocked-out clones. A further confirmation will be 
obtained by transient silencing the expression of PHOX2B by siRNA oligonucleotides, in IMR32 
cells.  
One of the biases of the CRISPR/Cas9 editing technology is the off-targeting effect, a mechanism 
by which the gRNA induces the Cas9 to cut in a not specific manner at the level of other 
sequences different from those of the gene that has to be edited. This is why it will be crucial 
to rescue the expression of PHOX2B in the clones to assess whether the de-regulated 
expression is indeed due to the missed expression of PHOX2B. 
The PHOX2B knocked-out cell model and the PGR overexpressing cells provide several new 
information about molecular defect induced by the mutated protein on newly identified 
PHOX2B target genes, and the possible mechanisms sustaining the pharmacological response 
 91 
 
to desogestrel. However, they provide a limited representation of human pathophysiology, 
being neuroblastoma cell lines, where the expression of PGR has been forced or the 
expression of PHOX2B completely ablated, thus not resembling the in vivo situation. To limit 
this bias, in the future, we will validate our data from this in vitro model in dissected rat 
hindbrains that have been sham-treated or treated with etonogestrel.  
 
Conclusion and perspectives 
 
Taken together, the results of my thesis support the hypothesis that CCHS is caused by a general 
transcription dysregulation. For the first time we provide the evidence that ion channels are 
PHOX2B and PHOX2A target genes and their expression may be dysregulated by the presence 
of PHOX2B mutant protein. In vivo, more than one mechanism is involved in CCHS 
pathogenesis, including loss-of-function and gain of function mechanisms. We reported the 
evidence that toxic functions acquired by mutant proteins could contribute to inducing 
aberrant expression of ion channels that can impair the restoring of the basal membrane 
potential after action potential, thus making neurons in the structure involved in breathing 
control less responsive to stimuli, such as the increased level of pCO2. In this light, it will 
important to study and better characterize the molecular mechanism underlying the new 
functions gained by the mutant proteins, in the perspective to develop pharmacological 
molecules able to counteract their toxic effect and rescue the normal activity of PHOX2B 
target genes. Our recent data on the progestin desogestrel strongly supported the idea that 
reduction of PHOX2B mutant protein can ameliorate CCHS symptoms. However, it is worth 
noting that drugs that act on mutant proteins also affect the expression of PHOX2B WT 
protein. An alternative pharmacological strategy, to by-pass the effect on PHOX2B, will be to 
target directly the de-regulated PHOX2B regulated genes, in the perspective of rescuing their 
activity. 
Our data open up a number of questions that need to be addressed. 
First, to evaluate whether deregulated ion channels, because of PHOX2B mutations, impaired the 
electrophysiological properties of neuronal cells, their activity will be tested in control and 
PHOX2B +7 Alanine expressing IMR32 cells and measure the total ionic currents in the 
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presence or not of voltage-gated Na+ and K+ blockers. An in vitro screening of compounds able 
to restore the expression and/or activity of deregulated ion channels will be performed. 
Second, we will explore the possibility that the desogestrel effect observed in two CCHS patients is 
mediated by the modulation of ion channels expression. Decreasing both mutant and WT 
PHOX2B may result in the restoration of a balanced expression of otherwise de-regulated 
PHOX2B target genes. 
Third, very little is known about the role of PHOX2A in CCHS pathogenesis, and its possible 
contribution to the toxic effect of mutant proteins on the expression of PHOX2B target genes. 
Studies on the transcriptional regulation of PHOX2B by the overexpressed PHOX2A/ PHOX2B 
+7 Alanine hetero-dimer in IMR32 cells and/or silencing of PHOX2A in the A6.4 clone will be 
performed. These findings might suggest novel strategies, targeting PHOX2A, for therapeutic 
intervention for this complex disease. 
Four, as the CCHS murine model die at born, and the neuroblastoma cell lines so far used do not 
recapitulate all the possible defects of neurons affected by PHOX2B mutations, we are setting 
up a new cellular model of CCHS based on induced pluripotent stem cells (iPS) technology, 
obtained by reprogramming fibroblast from CCHS patients and control skin biopsy to generate 
neurons and neuronal crest cells derivatives. The iPS will be differentiated into different types 
of neurons, to reveal possible defects during development, induced by the presence of 
PHOX2B mutations. The CCHS- and control-derived neurons will be used to further validate 
PHOX2B target genes, including the identified ion channels, and to screen molecules that can 
revert the possible developmental defects.  
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